DEVICES, COMPOSITIONS AND METHODS FOR IMAGING WITH RAMAN SCATTERING AND FOR SUPER-MULTIPLEX VIBRATIONAL IMAGING
20210068663 ยท 2021-03-11
Assignee
Inventors
- WEI MIN (Edgewater, NJ, US)
- LU WEI (Anhui, CN)
- ZHIXING CHEN (Beijing, CN)
- FANGHAO HU (New York, NY, US)
- YIHUI SHEN (Jiangsu, CN)
Cpc classification
A61B5/14532
HUMAN NECESSITIES
A61K45/06
HUMAN NECESSITIES
A61B5/14546
HUMAN NECESSITIES
A61B5/4887
HUMAN NECESSITIES
A61B5/0075
HUMAN NECESSITIES
G16C20/20
PHYSICS
International classification
A61B5/00
HUMAN NECESSITIES
A61K45/06
HUMAN NECESSITIES
Abstract
Exemplary methods, systems and computer-accessible medium for detecting at least one condition of at least one disease. In particular, it is possible to administer at least one composition to at least one patient, where the at least one composition includes at least one bond-edited compound configured to target at least one of a disease tissue or a pathogen. Further, it is possible to receive information related to the administration of the composition to the patient. It is also possible to detect the at least one bond-edited compound using a Raman scattering arrangement.
Claims
1. A non-transitory computer-accessible medium having stored thereon computer-executable instructions for detecting at least one condition of at least one disease, wherein, when a computer arrangement executes the instructions, the computer arrangement is configured to perform procedures comprising: receiving information related to an administration of the at least one composition to the at least one patient, wherein the at least one composition includes at least one bond-edited compound configured to target at least one of a disease tissue or a pathogen; and detecting the at least one bond-edited compound using a Raman scattering arrangement.
2. The computer-accessible medium of claim 1, wherein the bond-edited compound comprises one, two, three, four, five, six, seven, eight, nine, ten or more vibrational tags.
3. The computer-accessible medium of claim 2, wherein the vibrational tag is at least one of: an alkyne tag, an azide tag, an isotope label, or a combination of an alkyne tag and a carbon-deuterium bond tag.
4. The computer-accessible medium of claim 3, wherein the isotope label is a carbon-deuterium bond tag.
5. The computer-accessible medium of claim 1, wherein the bond-edited compound comprises: at least one vibrational tag selected from the group consisting of CC, CN, NNN, CCCC, CCCN, C-D, and CC-D, at least one .sup.13C atom or one deuterium atom, an amino acid, a nucleoside or a nucleotide, a fatty acid, a monosaccharide or a disaccharide, glucose, a glucose derivative or propargyl glucose, or a cytokine or chemokine.
6. The computer-accessible medium of claim 5, wherein the amino acid is an essential amino acid.
7. The computer-accessible medium of claim 6, wherein the essential amino acid is selected from the group consisting of histidine, isoleucine, leucine, lysing, methionine, phenylalanine, threonine, tryptophan and valine.
8. The computer-accessible medium of claim 1, wherein the bond-edited compound is selected from the group consisting of anti-cancer agents, anti-inflammatory agents, anti-bacterial agents, anti-fungal agents and anti-viral agents.
9. The computer-accessible medium of claim 2, wherein the vibrational tag is transferred from the bond-edited compound to a down-stream metabolite of the bond-edited compound, and is detected in the down-stream metabolite.
10. A system for detecting at least one condition of at least one disease, comprising: a computer hardware arrangement configured to: receive information related to the administration of at least one composition to at least one patient, wherein the at least one composition includes at least one bond-edited compound configured to target at least one of a disease tissue or a pathogen; and detect the at least one bond-edited compound using a Raman scattering arrangement.
11. The system of claim 10, wherein the bond-edited compound comprises one, two, three, four, five, six, seven, eight, nine, ten or more vibrational tags.
12. The system of claim 11, wherein the vibrational tag is at least one of: an alkyne tag, an azide tag, an isotope label, or a combination of an alkyne tag and a carbon-deuterium bond tag.
13. The system of claim 12, wherein the isotope label is a carbon-deuterium bond tag.
14. The system of claim 10, wherein the bond-edited compound comprises: at least one vibrational tag selected from the group consisting of CC, CN, NNN, CCCC, CCCN, C-D, and CC-D, at least one .sup.13C atom or one deuterium atom, an amino acid, a nucleoside or a nucleotide, a fatty acid, a monosaccharide or a disaccharide, glucose, a glucose derivative or propargyl glucose, or a cytokine or chemokine.
15. The system of claim 14, wherein the amino acid is an essential amino acid.
16. The system of claim 15, wherein the essential amino acid is selected from the group consisting of histidine, isoleucine, leucine, lysing, methionine, phenylalanine, threonine, tryptophan and valine.
17. The system of claim 10, wherein the bond-edited compound is selected from the group consisting of anti-cancer agents, anti-inflammatory agents, anti-bacterial agents, anti-fungal agents and anti-viral agents.
18. The system of claim 10, wherein the vibrational tag is transferred from the bond-edited compound to a down-stream metabolite of the bond-edited compound, and is detected in the down-stream metabolite.
19. A method for detecting at least one condition of at least one disease, comprising: administering at least one composition to at least one patient, wherein the at least one composition includes at least one bond-edited compound configured to target at least one of a disease tissue or a pathogen; and detecting the at least one bond-edited compound using a Raman scattering arrangement.
20. The method of claim 19, wherein the bond-edited compound comprises one, two, three, four, five, six, seven, eight, nine, ten or more vibrational tags.
21. The method of claim 20, wherein the vibrational tag is at least one of: an alkyne tag, an azide tag, an isotope label, or a combination of an alkyne tag and a carbon-deuterium bond tag.
22. The method of claim 21, wherein the isotope label is a carbon-deuterium bond tag.
23. The method of claim 19, wherein the bond-edited compound comprises at least one of: at least one vibrational tag selected from the group consisting of CC, CN, NNN, CCCC, CCCN, C-D, and CC-D, at least one .sup.13C atom or one deuterium atom, an amino acid, a nucleoside or a nucleotide, a fatty acid, a monosaccharide or a disaccharide, glucose, a glucose derivative or propargyl glucose, or a cytokine or chemokine.
24. The method of claim 23 wherein the amino acid is an essential amino acid.
25. The method of claim 24, wherein the essential amino acid is selected from the group consisting of histidine, isoleucine, leucine, lysing, methionine, phenylalanine, threonine, tryptophan and valine.
26. The method of claim 19, wherein the bond-edited compound is selected from the group consisting of anti-cancer agents, anti-inflammatory agents, anti-bacterial agents, anti-fungal agents and anti-viral agents.
27. The method of claim 20, wherein the vibrational tag is transferred from the bond-edited compound to a down-stream metabolite of the bond-edited compound, and is detected in the down-stream metabolite.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0057] Further objects, features and advantages of the present disclosure will become apparent from the following detailed description taken in conjunction with the accompanying FIGS. showing illustrative exemplary embodiments of the present disclosure, in which:
[0058]
[0059]
[0060]
[0061]
[0062]
[0063]
[0064]
[0065]
[0066]
[0067]
[0068]
[0069]
[0070]
[0071]
[0072]
[0073]
[0074]
[0075]
[0076]
[0077]
[0078]
[0079]
[0080]
[0081]
[0082]
[0083]
[0084]
[0085]
[0086]
[0087]
[0088]
[0089]
[0090]
[0091]
[0092]
[0093]
[0094]
[0095]
[0096]
[0097]
[0098]
[0099]
[0100]
[0101]
[0102]
[0103]
[0104]
[0105]
[0106]
[0107]
[0108]
[0109]
[0110]
[0111]
[0112]
[0113] Throughout the drawings, the same reference numerals and characters, unless otherwise stated, are used to denote like features, elements, components or portions of the illustrated exemplary embodiments. Moreover, while the present disclosure will now be described in detail with reference to the figures it is done so in connection with the illustrative exemplary embodiments and is not limited by the particular exemplary embodiments illustrated in the figures, and provided in the appended claims.
DETAILED DESCRIPTION OF EXEMPLARY EMBODIMENTS
[0114] The following detailed description is presented to enable any person skilled in the art to make and use the present disclosure. For purposes of explanation, specific nomenclature is set forth to provide a thorough understanding of the present invention. However, it will be apparent to one skilled in the art that these specific details are not required to practice the invention. Descriptions of specific applications are provided only as representative examples. The present disclosure is not intended to be limited to the exemplary embodiments shown, but is to be accorded the widest possible scope consistent with the principles and features disclosed herein.
[0115] As used herein, the term Raman scattering refers to a spectroscopic technique used to observe vibrational, rotational, and other low-frequency modes in a system. It relies on inelastic scattering, or Raman scattering, of monochromatic light, usually from a laser in the visible, near infrared, or near ultraviolet range. The laser light interacts with molecular vibrations, phonons or other excitations in the system, resulting in the energy of the laser photons being shifted up or down. The shift in energy gives information about the vibrational modes in the system. A variety of optical processes, both linear and nonlinear in light intensity dependence, are fundamentally related to Raman scattering. As used herein, the term Raman scattering includes, but is not limited to, stimulated Raman scattering (SRS), spontaneous Raman scattering, coherent anti-Stokes Raman scattering (CARS), surface-enhanced Raman scattering (SERS), Tip-enhanced Raman scattering (TERS) or vibrational photoacoustic tomography.
[0116] The exemplary system, method and computer accessible medium 4915, according to an exemplary embodiment of the present disclosure, can use alkyne as a vibrational tag coupled with narrow-band stimulated Raman scattering microscopy (SRS) for the detection of small molecules inside biological systems. The use of alkyne as a vibrational tag (e.g. a Raman tag) offers a large Raman cross-section enabling sensitive detection (See, e.g., References 13; 14). Additionally, the alkyne Raman peak can exhibit a narrow spectral width for the specific detection, which can reduce the probability of overlapping with other tags. Furthermore, the Raman peak of alkyne can lay exactly in the cell-silent region in the cell spontaneous Raman spectrum, bypassing the complex interference from vast pool of biomolecules in the fingerprint region. (See, e.g., FIG. Tb).
[0117] The exemplary SRS can be a sensitive vibrational imaging microscopy. By harnessing Einstein's stimulated emission process, the exemplary SRS can employ two-laser excitation (e.g., temporally and spatially overlapped Pump and Stokes lasers), boosting up the transition rate about 7 orders of magnitude as compared to the traditional spontaneous Raman microscopy, the transition process of which can be intrinsically weak (e.g., 10 to 12 orders of magnitude slower than fluorescence). (See, e.g., References 6; 8; 15). The exemplary SRS can be a bond-selective procedure with high specificity, in contrast with the spontaneous Raman imaging which can be a spectrum-based method. Instead of spreading the energy to the whole spectrum as in the spontaneous Raman imaging, the exemplary narrow-band SRS can focus its energy to the vibrational transition of a specific bond. A 6-ps pulse width can be chosen for both SRS pump and stokes lasers to achieve a spectral resolution of 5 cm.sup.1 for the detection of alkyne. The spectral width of the excitation profile from two combined lasers can be calculated to be 8 cm.sup.1, which can fit well within the spectral width of alkyne Raman peak that can be 14 cm.sup.1. (See, e.g.,
[0118] The exemplary SRS signal can offer linear concentration dependence to the analyte without non-specific background. Compared to a previously known nonlinear vibrational imaging procedure such coherent anti-Stokes Raman scattering (CARS) microscopy, which suffers from spectral distortion, unwanted non-resonant background, non-straightforward concentration dependence and coherent image artifact, the exemplary SRS can exhibit straightforward image interpretation and quantification without complications from non-resonant background and phase-matching conditions (See, e.g., References 7; 8; 16). Besides the above-mentioned advantages, SRS can also have its own distinctive characters as an imaging procedure. For example, SRS can be immune to fluorescence background as compared to spontaneous Raman microscopy that can suffer from large fluorescence background. In addition, SRS, as a nonlinear process, can offer intrinsic 3D sectioning capability. Moreover, by adopting near-infrared excitation, SRS can offer deeper penetration depth and less photo-toxicity, which can be well suited for imaging live cells, tissues and animals. Recently, narrow-band SRS has achieved unprecedented sensitivity down to approximately 1000 retinoic acid molecules and up to video rate imaging speed in vivo. (See, e.g., Reference 17).
[0119] Alkyne can be a metabolic labeling tag in fluorescence microscopy utilizing click-chemistry with azide-linked fluorescent tags (See, e.g., References 18-23). Unfortunately, this type of click-chemistry based fluorescence detection usually requires non-physiological fixation and subsequent dye staining and washing. The exemplary Raman detection, in contrast, does not have such requirements, since it can directly image vibrational modes of alkyne, bypassing the subsequent additional processes.
[0120] All of the above applications can show the universal and distinct advantage of the exemplary SRS coupled with alkyne tags to image the small molecule metabolites dynamics and drug distributions in the live cells, organisms and animals with minimum perturbation and high specificity and sensitivity, extending the repertoire of reporters for biological imaging beyond fluorophores.
Method for Obtaining Biological Information in a Living Cell or a Living Organism with Bond-Edited Compounds
[0121] One aspect of the present disclosure relates to a method for obtaining biological information in a living cell or a living organism with bond-edited compounds using Raman scattering. The method comprises the steps of introducing an effective amount of one or more bond-edited compounds into a live cell or a living organism, and detecting a vibrational tag in the cell or organism with Raman scattering. In some exemplary embodiments, the Raman scattering is SRS.
[0122] The term biological information as used herein, refers to spatial distribution of the targeted molecules, such as one-dimensional line, or two-dimensional or three-dimensional images, and non-imaging information, such as a simple signal intensity or local spectrum on a single location or its time dependence.
[0123] As used herein, the term bond-edited compounds refers to compounds having one or more chemical bond that may serve as a vibrational tag for detection by Raman scattering. Examples of chemical bond that may serve as a vibrational tag include, but are not limited to, carbon-carbon triple bond, carbon-nitrogen triple bond, azide bond, carbon-deuterium bond, phenol ring, .sup.13C modified carbon-carbon triple bond, .sup.13C modified carbon-nitrogen triple bond, .sup.13C modified azide bond, .sup.13C modified carbon-deuterium bond, .sup.13C modified phenol ring and combinations thereof.
[0124] As used herein, the term effective amount refers to an amount that, when introduced into a live cell or organism, is sufficient to reach a working concentration needed for SRS imaging. The effective amount would vary based on the type of bond-edited compound, as well as the cells or organisms that the bond-edited compound is introduced into. In some embodiments, an effective amount of a bond-edited compound is the amount that is sufficient to reach an in vivo concentration of 1 M to 100 mM, 3 M to 30 mM, 10 M to 10 mM, 100 M to 1 mM, 10 M to 1 mM or 10 M to 100 M in a target cell or organ. In some embodiments, an effective amount of a bond-edited compound comprising a triple bond is the amount that is sufficient to reach an in vivo concentration of 1 M to 10 mM, 3 M to 3 mM, 1 M to 1 mM or 30 M to 300 M. In some embodiments, an effective amount of a bond-edited compound comprising a triple bond is the amount that is sufficient to reach an in vivo concentration of about 100 M. In other embodiments, an effective amount of a bond-edited compound comprising a C-D bond is the amount that is sufficient to reach an in vivo concentration of 10 M to 100 mM, 30 M to 30 mM, 100 M to 10 mM or 300 M to 3 mM. In some embodiments, an effective amount of a bond-edited compound comprising a C-D bond is the amount that is sufficient to reach an in vivo concentration of about 1 mM.
[0125] In some exemplary embodiments, the bond-edited compounds are small molecules. As used herein, the term small molecules refers to low molecular weight organic compound having a molecular weight of 1000 daltons or less. In some exemplary embodiments, the small molecules have a size on the order of 10.sup.9 m. Examples of small molecules include, but are not limited to, water, ribonucleosides, ribonucleotides, deoxyribonucleoside, deoxyribonucleotide, amino acids, peptides, choline, monosaccharides, disaccharides, fatty acids, glucose, adenosine triphosphate, adenosine diphosphate, cholesterol, neurotransmitters, secondary messengers, and chemical drugs.
[0126] In some exemplary embodiments, said bond-edited compound contains one, two, three, four, five, six, seven, eight, nine, ten or more vibrational tags. The vibrational tags may be the same type of tags or a mixture of one or more different tags.
[0127] In some exemplary embodiments, said vibrational tag is an alkyne tag. In other exemplary embodiments, said vibrational tag is an azide tag. In still other exemplary embodiments, said vibrational tag is an isotope label. In a further exemplary embodiment, said isotope label is a carbon-deuterium tag. In yet still other exemplary embodiments, said vibrational tag is a combination of an alkyne tag and a carbon-deuterium tag.
[0128] In particular exemplary embodiments, said at least one vibrational tag comprises at least one vibrational tag selected from the group consisting of CC, CN, NNN, CCCC, CCCN, C-D, and CC-D.
[0129] In a further exemplary embodiment, the vibrational comprises at least one .sup.13C atom or one deuterium atom.
[0130] In some exemplary embodiments, the bond-edited compound is an amino acid.
[0131] In further exemplary embodiments, the amino acid is an essential amino acid.
[0132] In a still further exemplary embodiment, the essential amino acid is selected from the group consisting of histidine, isoleucine, leucine, lysing, methionine, phenylalanine, threonine, tryptophan and valine.
[0133] In other exemplary embodiments, the bond-edited compound is a nucleoside or a nucleotide.
[0134] In still other exemplary embodiments, the bond-edited compound is a fatty acid.
[0135] In still other exemplary embodiments, the bond-edited compound is a monosaccharide or a disaccharide. In a further exemplary embodiment, the bond-edited compound is glucose, a glucose derivative or propargyl glucose.
[0136] In still other exemplary embodiments, the bond-edited compound is a pharmaceutical agent, such as an anti-cancer agent, anti-inflammatory agent, anti-bacterial agent, anti-fungal agent and anti-viral agent.
[0137] In still other exemplary embodiments, the bond-edited compound is a cytokine or chemokine.
[0138] In some exemplary embodiments, the bond-edited compound is EU-.sup.13C2 having a molecular structure of formula 13:
##STR00010##
[0139] In some exemplary embodiments, the bond-edited compound is EdU-.sup.13C2 having a molecular structure of formula 3:
##STR00011##
[0140] In some exemplary embodiments, the bond-edited compound is EdU-.sup.13C having a molecular structure of formula 2:
##STR00012##
[0141] In some exemplary embodiments, the bond-edited compound is EdU-.sup.13C having a molecular structure of formula 14:
##STR00013##
[0142] In some exemplary embodiments, the bond-edited compound is alkyne-D-glucose having a molecular structure of formula S3:
##STR00014##
[0143] In some exemplary embodiments, the bond-edited compound is metabolized in the living cell or organism and the vibrational tag is transferred from the bond-edited compound to a down-stream metabolite of the bond-edited compound (See, e.g.,
[0144] In still other exemplary embodiments, the method comprises introducing into a live cell a mixture of bond-edited compounds that imaging with Raman scattering at two or more different wavelengths. In some related exemplary embodiments, the Raman scattering is SRS.
[0145] In still other exemplary embodiments, the method comprises introducing into a live cell a mixture of different bond-edited compounds that allow multiple color imaging with Raman scattering. In some related exemplary embodiments, the Raman scattering is SRS. In a particular exemplary embodiment, the mixture of different bond-edited compounds comprises EU-.sup.13C2, EdU-.sup.13C and 17-ODYA.
[0146] In some exemplary embodiments, the two or more bond-edited compounds target the same cellular component but at different time period (See, e.g.,
[0147] In still other exemplary embodiments, the method comprises introducing into a living cell a mixture of different bond-edited compounds that target different cellular components.
[0148] In still other exemplary embodiments, the method comprises introducing into a living organism a mixture of different bond-edited compounds that target different types of cells in the living organism.
[0149] In still other exemplary embodiments, the method comprises introducing into a living organism a mixture of different bond-edited compounds carrying different vibrational tags, and detecting the different vibrational tags with Raman scattering using a linear combination algorithm. In some related exemplary embodiments, the Raman scattering is SRS.
Exemplary Method for Making Bond-Edited Compounds
[0150] Another exemplary aspect of the present disclosure relates to a method for making a bond-edited compound.
[0151] In one exemplary embodiment, the bond-edited compound is synthesized by the route illustrated in
Exemplary Method of Detecting Disease Conditions
[0152] Another exemplary aspect of the present disclosure relates to a method for detecting a disease condition in a subject, comprising: administering to said subject a composition comprising a bond-edited compound targeting a disease tissue or pathogen, and detecting said bond-edited compound by Raman scattering.
[0153] In some exemplary embodiments, the subject is a mammal. Exemplary mammal subjects for use in accordance with the methods described herein include humans, monkeys, gorillas, baboons, zoo animals and domesticated animals, such as cows, pigs, horses, rabbits, dogs, cats, goats and the like.
[0154] In some exemplary embodiments, the disease condition is cancer.
[0155] In some exemplary embodiments, the disease condition is a neurodegenerative disease. In further exemplary embodiments, the neurodegenerative disease is selected from the group consisting of amyotrophic lateral sclerosis, Parkinson's, Alzheimer's and Huntington's.
[0156] In some exemplary embodiments, the disease condition is an inflammatory disease.
[0157] In some exemplary embodiments, the disease condition is a microbial infection.
[0158] In some exemplary embodiments, the disease condition is a bacterial infection.
[0159] In some exemplary embodiments, the disease condition is a viral infection.
[0160] In some exemplary embodiments, the disease condition is a fungal infection.
[0161] In some exemplary embodiments, the pathogen comprises bacteria.
Exemplary Method for Monitoring Treatment for a Disease Condition
[0162] Another exemplary aspect of the present disclosure relates to a method for monitoring treatment for a disease condition. The method comprises administering to said subject a composition comprising a bond-edited compound and detecting said bond-edited compound by SRS at a first time point, further administering to said subject said composition comprising a bond-edited compound and detecting said bond-edited compound by Raman scattering at a second time point, and comparing images obtained at the two time points.
[0163] In some exemplary embodiments, the first time point is a time point that is about or prior to the initiation of a treatment and the second time point is a time point that is after the initiation of the treatment.
[0164] In other exemplary embodiments, the first time point and the second time point are two time points during the course of a treatment.
[0165] In some exemplary embodiments, the treatment is a treatment for cancer.
[0166] In other exemplary embodiments, the treatment is a treatment for an inflammatory disease.
[0167] In other exemplary embodiments, the treatment is a treatment for a neurodegenerative disease.
Method for Screening an Agent
[0168] Another exemplary aspect of the present disclosure relates to a method for screening an agent. The method comprises administering said agent and at least one bond-edited compound to a live cell or organism, detecting the bond-edited compound in the live cell or organism using Raman scattering, and selecting a candidate agent based on one or more predetermined criteria, such as the uptake, accumulation, trafficking, or degradation of the said bond-edited compound in the said live cell or organism.
[0169] In some exemplary embodiments, the candidate agent is an anti-cancer drug.
[0170] In some exemplary embodiments, the bond-edited compound is selected from the group consisting of amino acid, nucleic acid, ribonucleic acid and glucose derivatives.
[0171] In some exemplary embodiments, the candidate agent is a skin regenerating agent.
[0172] In some exemplary embodiments, the candidate agent is a cosmetic agent.
Exemplary Method for Tracing a Cellular Process in a Live Cell with Raman Scattering
[0173] Another exemplary aspect of the present disclosure relates to a method for tracing a cellular process in a live cell with Raman scattering. The method comprises introducing into a live cell a bond-edited compound, and following the physical movement or the chemical reaction or the biological interaction of the bond-edited compound within the cell by SRS.
[0174] In some exemplary embodiments, the cellular processes are selected from the group consisting of DNA replication, RNA synthesis, protein synthesis, protein degradation, glucose uptake and drug uptake.
Exemplary Composition for Labeling Cells with Bond-Edited Compounds
[0175] Another exemplary aspect of the present disclosure relates to a composition for labeling a target cell with at least one bond-edited compound. In some exemplary embodiments, the composition is a culture medium comprising at least one bond-edited compound containing at least one vibrational tag. The at least one bond-edited compound may be selected based on the type of the target cell or a target component(s) within the target cell.
[0176] In some exemplary embodiments, the culture medium comprises a plurality of amino acids, wherein over 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% of the amino acids are tagged with one or more vibrational tag. In other exemplary embodiments, the culture medium comprises a plurality of amino acids, wherein all amino acids are tagged with one or more vibrational tag.
[0177] In some exemplary embodiments, the culture medium comprises two, three, four, five, six, seven, eight, nine, ten or more different bond-edited compounds.
Exemplary Device for Imaging a Living Cell or a Living Organism with Bond-Edited Compounds
[0178] Another exemplary aspect of the present disclosure relates to a device for imaging bond-edited compounds by Raman scattering. The device comprises a first single-wavelength laser source that produces a pulse laser beam of a first wavelength, a second single-wavelength laser source that produces a pulse laser beam of a second wavelength, a modulator that modulates either the intensity or the frequency or the phase or the polarization or the combination of the above of the pulse laser beam of one of the first or second laser source, a photodetector that is capable of detecting SRS or CARS or spontaneous Raman scattering or the combination of the above from a biosample, and a computer.
[0179] In some exemplary embodiments, the energy difference between the photons produced by the first laser radiation and the photon produced by the second laser radiation matches with the energy of the vibrational transitions of the targeted vibrational tags. Photodetector of SRS detects part or all of the first laser beam or the second laser beam. The output of the photodetector (which could be a photodiode) is further processed by a lock-in amplifier or a resonant circuit.
[0180] Another exemplary aspect of the present disclosure relates to an apparatus for providing radiation to at least one structure, comprising: a radiation providing arrangement which is configured to provide a pump radiation and a stokes radiation, each at a fixed wavelength, whose energy difference is between about 2000 and 2500 wavenumbers.
[0181] In some exemplary embodiments, the radiation providing arrangement is a laser source.
Exemplary System and Method for Super-Multiplex Vibrational Imaging
[0182] For example, carrying out stimulated Raman scattering under electronic pre-resonance conditions (e.g., epr-SRS) can facilitate imaging with exquisite vibrational selectivity and sensitivity (e.g., down to 250 nM with 1-ms) in living cells. A palette of triple-bond-conjugated near-infrared dyes that each display a single epr-SRS peak in the cell-silent spectral window, and that with available fluorescent probes give 24 resolvable colors with potential for further expansion was created. Proof-of-principle experiments on neuronal co-cultures and brain tissues reveal cell-type dependent heterogeneities in DNA and protein metabolism under physiological and pathological conditions, underscoring the potential of this super-multiplex optical imaging approach for untangling intricate interactions in complex biological systems. SRS microscopy, developed for label-free imaging of chemical bonds, uses nonlinear Raman effects to accelerate weak vibrational transition by 108 times in the far field and thereby overcomes the sensitivity or biocompatibility limitations of other Raman imaging modalities. Coupling SRS with strong vibrational tags such as alkynes (e.g., CC) facilitates effective imaging of diverse biomolecules, but detection sensitivity can still be limited to about 15 mM for typical chemical bonds such as C H and 200 M for the stronger CC bond that leaves many targets (e.g., such as metabolites, proteins, RNA, organelles) out of reach.
[0183] The sensitivity limits can be associated with SRS microscopy having so far always operated in the non-resonance region, with the pump laser energy (e.g., pump) well below the molecular absorption peak energy (e.g., 0) (e.g.,
[0184] In the exemplary first proof-of-principle epr-SRS microscopy demonstration, ATTO740-labeled 5-Ethynyl-2-deoxyuridine (e.g., EdU, a metabolic target for newly synthesized DNA) in HeLa cells was imaged with a short pixel dwell time of 4 s (e.g., 0.4 s per 320-by-320 frame) (e.g., see
[0185] To demonstrate the versatility of epr-SRS imaging, the ATTO740 immuno-labeled intracellular proteins were imaged, which were (e.g.,
[0186] An exemplary epr-SRS reporter dye palette was developed. Characterization of 28 commercial dyes across a wide range of 0 (e.g.,
where vib can be the vibrational transition energy and K can be a collection of frequency-independent factors of the dyes. An epr-SRS excitation region as 2<0pump<6 (e.g.,
[0187] 5 CC peaks were selected to demonstrate the multiplex imaging capability (e.g.,
[0188] The epr-SRS dye palette can be expanded further, especially when going beyond conjugated CC bonds and targeting triple bonds such as alkynes (e.g., CC) and nitriles (e.g., CN) that display a single sharp Raman peak in the wide silent window (e.g., from 1800 to 2800 cm.sup.1).sup.12-15,20. The challenge here can be that the triple bonds can be coupled with an electronic transition to enable pre-resonance enhancement, which can depend sensitively on the electronic-vibrational coupling strength.sup.16. Hence, simply installing a triple bond onto an arbitrary position of a dye can most often not yield satisfying signals. A new library of near-infrared dyes (e.g.,
can be the reduced mass. As illustrated by the x- and y-axes in
[0189] Most of the dyes were synthesized (e.g., including their .sup.13C and .sup.15N isotopologues) in the exemplary conceived library (e.g.,
[0190] The exemplary newly developed epr-SRS vibrational palette has biocompatibility that ensures sufficient cell viability, the utilized photostability and effective linear unmixing to enable proof-of-principle imaging on live HeLa cells. After being separately stained with individual dyes and then mixed together, these cells are subjected to 16-color live-cell imaging, which quadruples the number of color channels typically achieved by fluorescence alone. The resultant image shown in
[0191] Neuronal systems were examined under proteasomal stress. Proteostasis, the balance between new protein synthesis and degradation of aberrant proteins, can be precisely regulated through cellular quality control, particularly the ubiquitin-proteasome system, with proteasome dysfunction implicated in many neurodegenerative diseases and aging processes. When studying individual cell types under proteasomal stress (e.g., modeled by applying proteasome inhibitor MG132), astrocytes were found to be more resistant than neurons and oligodendrocytes. Because such cell-type dependent vulnerability can be unexplored in more realistic environments where different cells can co-exist, 8-color imaging was used to examine the global proteostasis stress in neuronal co-cultures with largely preserved astrocyte-neuron coupling. As expected, applying MG132 (e.g.,
[0192] While the above proof-of-principle observations demonstrate already the potential of the exemplary procedure, it can be improved further along multiple fronts. First, the MARS dye palette can be potentially expanded to 50 or more colors by filling the rather broad cell-silent window with individual sharp peaks from novel vibrational moieties. Second, genetically encoded infrared proteins could also be engineered to serve as vibrational reporters. Third, hyper-spectral imaging can be implemented to realize faster and simultaneous signal acquisition.
[0193]
[0194] As shown in
[0195] Further, the exemplary processing arrangement 4905 can be provided with or include an input/output arrangement 4935, which can include, for example a wired network, a wireless network, the internet, an intranet, a data collection probe, a sensor, etc. As shown in
[0196] The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to carry out the method of the present disclosure and is not intended to limit the scope of the invention. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperature, etc.), but some experimental error and deviation should be accounted for. Unless indicated otherwise, parts are parts by weight, molecular weight is weight average molecular weight, temperature is in degrees Centigrade and pressure is at or near atmospheric.
EXAMPLES
Example 1: In Vitro and In Vivo Labeling with Deuterium Tags
[0197] In the examples described below, three major technical advances are being implemented, together with a series of biological applications on complex tissues and model animals in vivo (FIG. Ta). First, we optimized the chemical composition of the deuterated culture medium that achieved much higher deuterium labeling efficiency, and improved imaging sensitivity and speed of our SRS instrumentation. These optimizations allow us to demonstrate time-lapse imaging of protein synthesis dynamics within single live cells. Second, we successfully imaged protein degradation in live HeLa cells by targeting Raman peak of methyl group (CH.sub.3) for the pre-existing protein pools and then employing a recently developed linear combination algorithm on measured SRS images at 2940 cm.sup.1 and 2845 cm.sup.1 channels. Third, inspired by the classic pulse-chase analysis of complex protein dynamics, two-color pulse-chase imaging was accomplished by rationally dividing D-AAs into two structurally different sub-sets that exhibit resolvable vibrational modes, as demonstrated by tracking aggregate formation of mutant huntingtin (mHtt) proteins. Finally, going beyond the cellular level to visualizing more complex tissues and animals in vivo, we imaged the spatial distribution of newly synthesized proteins inside live brain tissue slices and in both developmental embryonic zebrafish and mice (
Exemplary Materials and Methods
[0198] Stimulated Raman scattering microscopy. An integrated laser (picoEMERALD with custom modification, Applied Physics & Electronics, Inc.) was used as the light source for both Pump and Stokes beams. Briefly, picoEMERALD provides an output pulse train at 1064 nm with 6 ps pulse width and 80 MHz repetition rate, which serves as the Stokes beam. The frequency-doubled beam at 532 nm is used to synchronously Seed a picosecond optical parametric oscillator (OPO) to produce a mode-locked pulse train (the idler beam of the OPO is blocked with an interferometric filter) with 5-6 ps pulse width. The wavelength of the OPO is tunable from 720 to 990 nm, which serves as the Pump beam. The intensity of the 1064 nm Stokes beam is modulated sinusoidally by a built-in electro-optic modulator (EOM) at 8 MHz with a modulation depth of more than 95%. The Pump beam is spatially overlapped with the Stokes beam with a dichroic mirror inside picoEMERALD. The temporal overlap between Pump and Stokes pulse trains is ensured with a built-in delay stage and optimized by the SRS signal of pure dodecane liquid.
[0199] Pump and Stokes beams are coupled into an inverted laser-scanning microscope (FV1200MPE, Olympus) optimized for near IR throughput. A 60 water objective (UPlanAPO/IR, 1.2 N.A., Olympus) with high near IR transmission is used for all cellular level imaging, and a 25 water objective (XLPlan N, 1.05 N.A., MP, Olympus) with both high near IR transmission and large field of view is used for brain tissue and in vivo imaging. The Pump/Stokes beam size is matched to fill the back-aperture of the objective. The forward going Pump and Stokes beams after passing through the sample are collected in transmission with a high N.A. condenser lens (oil immersion, 1.4 N.A., Olympus), which is aligned following Kohler illumination. A telescope is then used to image the scanning mirrors onto a large area (10 mm by 10 mm) Si photodiode (FDS1010, Thorlabs) to descan beam motion during laser scanning. The photodiode is reverse-biased by 64 V from a DC power supply to increase both the saturation threshold and response bandwidth. A high O.D. bandpass filter (890/220 CARS, Chroma Technology) is used to block the Stokes beam completely and transmit the Pump beam only. The output current of the photodiode is electronically pre-filtered by an 8-MHz band-pass filter (KR 2724, KR electronics) to suppress both the 80 MHz laser pulsing and the low-frequency contribution due to laser scanning across the scattering sample. It is then fed into a radio frequency lock-in amplifier (HF2LI, Zurich instrument) terminated with 50 to demodulate the stimulated Raman loss signal experienced by the Pump beam. The R-output of the lock-in amplifier is fed back into the analog interface box (FV10-ANALOG) of the microscope.
[0200] For HeLa cell imaging and brain tissue imaging, the time constant of the lock-in amplifier is set for 8 s, and the images are acquired by a 12.5 s pixel dwell time, corresponding to 3.3 s for a 512-by-512 pixel frame. For neurons and in vivo imaging of embryonic zebrafish and mice livers and intestines, the time constant is set to be 20 s, and the images are acquired by a 40 s of pixel dwell time, corresponding to 10.5 s for a 512-by-512 pixel frame. Laser powers after 60 IR objective used for cell imaging are: 100 mW for modulated Stokes beam and 112 mW for the Pump beam at 2133 cm.sup.1, 2000 cm.sup.1 and 1655 cm.sup.1 channels; 50 mW for modulated Stokes beam and 56 mW for Pump beam at 2940 cm.sup.1 and 2845 cm.sup.1 channels. Laser powers after 25 objective used for tissue and in vivo imaging are: 134 mW for modulated Stokes beam; 120 mW for the Pump beam of 2133 cm.sup.1, 2000 cm.sup.1 and 1655 cm.sup.1 channels; 67 mW for modulated Stokes beam and 60 mW for Pump beam at 2940 cm.sup.1 and 2845 cm.sup.1 channels.
[0201] Metabolic incorporation of deuterated amino acids. For HeLa cells: cells are Seeded on a coverslip in a petri-dish with 2 mL of regular medium for 20 h, and then replaced with D-AA medium (or group I and group II D-AA media) for designated amount of time. The coverslip is taken out to make an imaging chamber filled with PBS for SRS imaging. For hippocampal neurons, the dissociated neurons from newborn mice are Seeded for 10 days in regular Neurobasal A medium, and then replaced with the corresponding D-AA medium for designated amount of time before imaging. For organotypic brain slice, 400 m thick, P10 mouse brain slices are cultured on Millicell-CM inserts (PICM03050, millipore) in 1 mL CD-MEM culture medium for 2 h, and then change to in 1 mL CD-neurobasal a culture medium for another 28 h before imaging. For detailed recipe of D-AA media and in vivo labeling procedure in zebrafish and mice. (See Supporting Information). The experimental protocol for in vivo mice experiments (AC-AAAG2702) and zebrafish experiments (AC-AAAD6300) were approved by Institutional Animal Care and Use Committee at Columbia University.
[0202] Spontaneous Raman spectroscopy. The spontaneous Raman spectra were acquired using a laser Raman spectrometer (inVia Raman microscope, Ranishaw) at room temperature. A 27 mW (after objective) 532 nm diode laser was used to excite the sample through a 50, N.A. 0.75 objective (NPLAN EPI, Leica). The total data acquisition was performed during 60 seconds using the WiRE software. All the spontaneous Raman spectra have subtracted the PBS solution as background.
[0203] Image progressing. Images are acquired with FluoView scanning software and assigned color or overlaid by ImageJ. Linear combination was processed with Matlab. Graphs were assembled with Adobe Illustrator.
[0204] Culture medium. Regular HeLa cells medium was made of 90% DMEM medium (11965, Invitrogen), 10% FBS (10082, Invitrogen) and 1 penicillin/streptomycin (15140, Invitrogen); regular hippocampal neuron medium was made of Neurobasal A Medium (10888, Invitrogen), 1B27 serum free supplement (17504, Invitrogen) and 0.5 mM glutamine (25030, Invitrogen).
[0205] Htt-mEos2 plasmid construct and transfection. mHtt94Q-mEos2 plasmid was constructed by replacing CFP gene sequence in pTreTight-Htt94Q-CFP plasmid (Addgene, 23966) with mEos2 gene sequence from pRSETa-mEos2 plasmid (Addgene, 20341). For transfection of mHtt-mEos2 plasmid in HeLa cells, 4 g mHtt94Q-mEos2 plasmid was transfected using Transfection Reagent (FuGene, Promega).
[0206] Optimized Deuterium-Labeling Media 1) D-AA medium (CD-DMEM) for HeLa cells: adapted from regular recipe of DMEM medium (11965, Invitrogen). The D-AA culture medium for HeLa cells was made with 90% CD-DMEM, 10% FBS (10082, Invitrogen) and 1 penicillin/streptomycin (15140, Invitrogen).
TABLE-US-00001 Amino acids Concentration Product company components (mM) and catalog number Glycine-d.sub.5 0.4 DLM-280, Cambridge isotope L-ArginineHCl-d.sub.7 0.398 DLM-541, Cambridge isotope L-Cysteine2HCl 0.2 C6727, SIGMA (regular)* L-Glutamine-d.sub.5 4.0 DLM-1826, Cambridge isotope L-HistidineHClH.sub.2O 0.2 H5659, SIGMA (regular)* L-Isoleucine-d.sub.10 0.802 DLM-141, Cambridge isotope L-Leucine-d.sub.10 0.802 DLM-567, Cambridge isotope L-LysineHCl-d.sub.8 0.798 616214, ALDRICH (Isotech) L-Methionine-d.sub.3 0.201 DLM-431, Cambridge isotope L-Phenylalanine-d.sub.8 0.4 DLM-372, Cambridge isotope L-Serine-d.sub.3 0.4 DLM-582, Cambridge isotope L-Threonine 0.798 T8441, SIGMA (regular)* L-Tryptophan 0.078 T8941, SIGMA (regular)* L-Tyrosine-d.sub.2 0.398 DLM-2317, Cambridge isotope L-Valine-d.sub.8 0.803 DLM-488, Cambridge isotope [0207] Other components (vitamins, Inorganic Salts and glucose) are exactly the same as in the regular DMEM medium (11965, Invitrogen).
[0208] *The reasons these 4 amino acids are remain in their regular forms are because: first, their deuterated forms have limited number of side chain deuterium and are also relatively expensive; second, their occurrence (percentage) in mammalian cell proteins are small. Thus the lack of the deuterated version for these 4 amino acids would not influence the general deuterium labeling efficiency for CD-DMEM. Same reason applies to below media.
[0209] 2) D-AA medium (CD-Neurobasal A) for hippocampal neuron culture and organotypic brain slices: adapted from regular recipe of Neurobasal A medium (10888, Invitrogen). The D-AAs culture medium for hippocampal neurons was made of CD-Neurobasal A Medium, 1B27 serum free supplement (17504, Invitrogen) and 0.5 mM glutamine-d.sub.5 (DLM-1826, Cambridge isotope). The CD-Neurobasal A culture medium for organotypic brain slices was made of CD-Neurobasal A Medium, 1B27 serum free supplement (17504, Invitrogen), 0.5% glucose (15023, Invitrogen), 2 mM glutamine-d.sub.5 (DLM-1826, Cambridge isotope) and 1 penicillin/streptomycin (15140, Invitrogen).
TABLE-US-00002 Amino acids Concentration Product company components (mM) and catalog number Glycine-d.sub.5 0.4 DLM-280, Cambridge isotope L-Alanine-d.sub.4 0.022 DLM-250, Cambridge isotope L-ArginineHCl-d.sub.7 0.398 DLM-541, Cambridge isotope L-Asparagine-d.sub.8 0.006 672947 ALDRICH (Isotech) L-Cysteine2HCl 0.26 C6727, SIGMA (regular)* L-HistidineHClH.sub.2O 0.2 H5659, SIGMA (regular)* L-Isoleucine-d.sub.10 0.802 DLM-141, Cambridge isotope L-Leucine-d.sub.10 0.802 DLM-567, Cambridge isotope L-LysineHCl-d.sub.8 0.798 616214, ALDRICH (Isotech) L-Methionine-d.sub.3 0.201 DLM-431, Cambridge isotope L-Phenylalanine-d.sub.8 0.4 DLM-372, Cambridge isotope L-Proline-d.sub.7 0.067 DLM-487, Cambridge isotope L-Serine-d.sub.3 0.4 DLM-582, Cambridge isotope L-Threonine 0.798 T8441, SIGMA (regular)* L-Tryptophan 0.078 T8941, SIGMA (regular)* L-Tyrosine-d.sub.2 0.398 DLM-2317, Cambridge isotope L-Valine-d.sub.8 0.803 DLM-488, Cambridge isotope [0210] Other components (vitamins, Inorganic Salts and glucose) are exactly the same as in the regular Neurobasal A medium (10888, Invitrogen).
[0211] 3) Group I D-AA medium for HeLa cells. The group I D-AA culture medium for HeLa cells was made with 90% group I D-AA medium, 10% FBS (10082, Invitrogen) and 1 penicillin/streptomycin (15140, Invitrogen).
TABLE-US-00003 Amino acids Concentration Product company components (mM) and catalog number Glycine 0.4 50046, SIGMA (regular) L-ArginineHCl 0.398 A6969, SIGMA (regular) L-Cysteine2HCl 0.2 C6727, SIGMA (regular) L-Glutamine 4.0 G8540, SIGMA (regular) L-HistidineHClH.sub.2O 0.2 H5659, SIGMA (regular) L-Isoleucine-d.sub.10 0.802 DLM-141, Cambridge isotope L-Leucine-d.sub.10 0.802 DLM-567, Cambridge isotope L-LysineHCl 0.798 L8662 SIGMA (regular) L-Methionine 0.201 M5308 SIGMA (regular) L-Phenylalanine 0.4 P5482 SIGMA (regular) L-Serine 0.4 S4311 SIGMA (regular) L-Threonine 0.798 T8441, SIGMA (regular) L-Tryptophan 0.078 T8941, SIGMA (regular) L-Tyrosine 0.398 T8566 SIGMA (regular) L-Valine-d.sub.8 0.803 DLM-488, Cambridge isotope [0212] Other components (vitamins, Inorganic Salts and glucose) are exactly the same as in the regular DMEM medium (11965, Invitrogen).
[0213] 4) Group II D-AA medium for HeLa cells. The group II D-AA culture medium for HeLa cells was made with 90% group II D-AA medium, 10% FBS (10082, Invitrogen) and 1 penicillin/streptomycin (15140, Invitrogen).
TABLE-US-00004 Amino acids Concentration Product company components (mM) and catalog number Glycine-d.sub.5 0.4 DLM-280, Cambridge isotope L-ArginineHCl-d.sub.7 0.398 DLM-541, Cambridge isotope L-Cysteine2HCl 0.2 C6727, SIGMA (regular) L-Glutamine-d.sub.5 4.0 DLM-1826, Cambridge isotope L-HistidineHClH.sub.2O 0.2 H5659, SIGMA (regular) L-Isoleucine 0.802 17403 SIGMA (regular) L-Leucine 0.802 L8912 SIGMA (regular) L-LysineHCl-d.sub.8 0.798 616214, ALDRICH (Isotech) L-Methionine-d.sub.3 0.201 DLM-431, Cambridge isotope L-Phenylalanine-d.sub.8 0.4 DLM-372, Cambridge isotope L-Serine-d.sub.3 0.4 DLM-582, Cambridge isotope L-Threonine 0.798 T8441, SIGMA (regular) L-Tryptophan 0.078 T8941, SIGMA (regular) L-Tyrosine-d.sub.2 0.398 DLM-2317, Cambridge isotope L-Valine 0.803 V0513 SIGMA (regular) [0214] Other components (vitamins, Inorganic Salts and glucose) are exactly the same as in the regular DMEM medium (11965, Invitrogen).
[0215] 5) D-AA medium (CD-MEM) for organotypic brain slice: adapted from regular recipe of MEM medium (11095, Invitrogen). The CD-MEM culture medium for organotypic brain slice was made with 90% CD-MEM, 10% FBS (10082, Invitrogen), 0.5% glucose (15023, Invitrogen) and 1 penicillin/streptomycin (15140, Invitrogen).
TABLE-US-00005 Amino acids Concentration Product company components (mM) and catalog number L-ArginineHCl-d.sub.7 0.597 DLM-541, Cambridge isotope L-Cysteine2HCl 0.1 C6727, SIGMA (regular)* L-Glutamine-d.sub.5 2.0 DLM-1826, Cambridge isotope L-HistidineHClH.sub.2O 0.2 H5659, SIGMA (regular)* L-Isoleucine-d.sub.10 0.397 DLM-141, Cambridge isotope L-Leucine-d.sub.10 0.397 DLM-567, Cambridge isotope L-LysineHCl-d.sub.8 0.399 616214, ALDRICH (Isotech) L-Methionine-d.sub.3 0.1 DLM-431, Cambridge isotope L-Phenylalanine-d.sub.8 0.19 DLM-372, Cambridge isotope L-Threonine 0.403 T8441, SIGMA (regular)* L-Tryptophan 0.049 T8941, SIGMA (regular)* L-Tyrosine-d.sub.2 0.199 DLM-2317, Cambridge isotope L-Valine-d.sub.8 0.393 DLM-488, Cambridge isotope [0216] Other components (vitamins, Inorganic Salts and glucose) are exactly the same as in the regular MEM medium (11095, Invitrogen).
[0217] 6) For zebrafish: Wild-type zebrafish embryos at the 1-cell stage were injected with 1 nL D-AA solution and allowed to develop normally for another 24 h. The zebrafish embryos at 24 hpf were manually dechorionated before imaging. D-AA solution was made of 150 mg uniformly deuterium-labeled amino acid mix (20 aa) (DLM-6819, Cambridge Isotope) dissolved in 1 mL PBS, with subsequent filtration using Millipore sterile syringe Filters (0.22 m, SLGV033RS).
[0218] 7) For mice: 1. Oral administration: 3-week-old mice were fed with D-AA containing drinking water for 12 days before harvesting the liver and intestine tissues. The drinking water was made of 500 mg uniformly deuterium-labeled amino acid mix (20 aa) (DLM-6819, Cambridge Isotope) dissolved in 200 ml PBS, with subsequent filtration using Millipore sterile syringe Filters (0.22 m, SLGV033RS). 2. Intraperitoneal injection: 3-week-old mice were injected with 500 l D-AAs solution at the 0.sup.th h, 12.sup.th h and 24.sup.th h. The tissues were then harvested at the 36.sup.th h after the first injection. D-AA solution was made of 500 mg uniformly deuterium-labeled amino acid mix (20 aa) (DLM-6819, Cambridge Isotope) dissolved in 2 ml PBS solutions, with subsequent filtration using Millipore sterile syringe Filters (0.22 m, SLGV033RS).
Example 1a: Sensitivity Optimization and Time-Lapse Imaging of the De Novo Proteome Synthesis Dynamics
[0219] The cell culture medium reported previously was prepared by supplying uniformly deuterium-labeled whole set of amino acids to a commercially available medium that is deficient of leucine, lysine and arginine (Wei L, Yu Y, Shen Y, Wang M C, Min W (2013) Vibrational imaging of newly synthesized proteins in live cells by stimulated Raman scattering microscopy. Proc. Natl. Acad. Sci. USA. 110:11226-11231). Due to the presence of other regular amino acids already in the commercial medium, the resulting partially deuterated medium has only about 60% deuteration efficiency. In the present paper, we custom prepared new media that replace nearly all the regular amino acids by the D-AA counterparts (details in Supporting Information). As shown in the spontaneous Raman spectra (
[0220] With much-improved sensitivity, protein synthesis can now be imaged with superb spatial and temporal resolutions. Spatially, we visualized newly synthesized proteins from fine structures (likely dendritic spines, indicated by arrow heads) of live neurons (
Example 1b: SRS Imaging of Protein Degradation in Live HeLa Cells
[0221] Besides imaging protein synthesis, our imaging platform offers the ability to probe protein degradation simultaneously. Experimentally, we intend to probe the pre-existing protein pool by targeting the CH.sub.3 showing a strong peak at 2940 cm.sup.1, as newly synthesized proteins will be mostly carrying C-D peaked around 2133 cm.sup.1. However, the 2940 cm.sup.1 CH.sub.3 protein channel is known to suffer from undesired crosstalk from the CH.sub.2 lipid signal peaked at 2845 cm.sup.1. To obtain a clean protein component, we adopt two-color SRS imaging at both 2940 cm.sup.1 and 2845 cm.sup.1 channels followed by a linear combination algorithm which has been effectively applied in cells, tissues and animals. The subsequently obtained images show the pure distribution of old protein pools (exclusively from CH.sub.3) and the distribution of lipids (exclusively from CH.sub.2), respectively. Hence protein degradation could be tracked by imaging the old protein distributions over time when cells are growing in the D-AA medium.
[0222]
[0223] Retrieval of pure CH.sub.3 and CH.sub.2 signals by linear combination between 2940 cm.sup.1 and 2845 cm.sup.1 channels was conducted employing equations follow Lu F-K et al. (2012) Multicolor stimulated Raman scattering microscopy. Mol. Phys. 110:1927-1932; and Yu Z et al. (2012) Label-free chemical imaging in vivo: three-dimensional non-invasive microscopic observation of amphioxus notochord through stimulated Raman scattering (SRS). Chem. Sci. 3:2646-2654. Pure CH.sub.3 signal can be retrieved as [c].sub.protein 5.2*(2940 cm.sup.1 signal)-4.16*(2845 cm.sup.1 signal); Pure CH.sub.2 signal can be retrieved as [c].sub.lipid 1.2*(2845 cm.sup.1 signal)0.3*(2940 cm.sup.1 signal). This algorithm was tested with skin tissue samples, yielding similar results as reported in Lu F-K et al. (2012) Multicolor stimulated Raman scattering microscopy. Mol. Phys. 110:1927-1932; and Yu Z et al. (2012) Label-free chemical imaging in vivo: three-dimensional non-invasive microscopic observation of amphioxus notochord through stimulated Raman scattering (SRS). Chem. Sci. 3:2646-2654.
Example 1c: Two-Color Pulse-Chase SRS Imaging of Two Sets of Temporally Defined Proteins
[0224] Inspired by the popular pulse-chase analysis in classic autoradiography techniques and recent two-color BONCAT imaging (Beatty K E, Tirrell D A (2008) Two-color labeling of temporally defined protein populations in mammalian cells. Bioorg. Med. Chem. Lett. 18:5995-5999), we aim to exploit another dimension of probing dynamic protein metabolism with two-color pulse-chase imaging of proteins labeled at different times. To do so, we need to rationally divide total D-AAs into two sub-sets with distinct Raman spectra. We reasoned that Raman peaks of C-D stretching are closely related to their chemical environments, thus the structural difference between D-AAs should lead to diverse Raman peak positions and shapes. We then examined the spontaneous Raman spectra of each D-AA sequentially, and subsequently identified two subgroups. Group I contains three amino acids, leuine-d10, isoleucine-d10 and valine-d8, structurally known as branched-chain amino acids (
[0225] The rest of D-AAs without branched chains are then categorized into group II, all of which show a prominent Raman peak around 2133 cm.sup.1 (three examples shown in
[0226] We now chose the mutant huntingtin (mHtt) protein in Huntington's disease as our model system for pulse-chase imaging demonstration. It is believed that Huntington's disease is caused by a mutation from normal huntingtin gene to mHtt gene expressing aggregation-prone mHtt proteins with poly-glutamine (polyQ) expansion (Walker FO (2007) Huntington's Disease. The Lancet. 369: 218-228). For easy visualization by fluorescence, we tagged mHtt (with 94Q) with a fluorescent protein marker, mEos2. As illustrated by the cartoon in
[0227] Fluorescence overlaid with bright field image informs us the formation of a large aggregate triggered by aggregation-prone polyQ expansion in mHtt94Q-mEos2 (
[0228] In order to achieve SRS imaging of pure group I D-AA labeled protein distribution and pure group II D-AA labeled protein distribution simultaneously, we construct a robust linear combination algorithm to retrieve the underlying pure concentration information for two-color pulse-chasing imaging similar to the one presented above from Lu F-K et al. (2012) Multicolor stimulated Raman scattering microscopy. Mol. Phys. 110:1927-1932; and Yu Z et al. (2012) Label-free chemical imaging in vivo: three-dimensional non-invasive microscopic observation of amphioxus notochord through stimulated Raman scattering (SRS). Chem. Sci. 3:2646-2654. Since SRS signals exhibit linear concentration dependence with analyte concentrations, two chemical species with different Raman spectra can be retrieved quantitatively with two-color SRS imaging. Hence, based on the spectra shown in
[0229] The proper algorithm with the corresponding cross-talk coefficients is constructed with SRS images of standard reference samples, i.e., pure group I D-AA labeled protein and pure group II D-AA labeled protein. To do so, we labeled HeLa cells with only group I D-AA medium
[0230] For any sample labeled with both groups of D-AAs, the measured SRS signals at 2067 cm.sup.1 and 2133 cm.sup.1 channels can be written as the following, with linear relationship to group I D-AA and group II D-AA concentrations ([c]group I and [c]group II):
where i.sub.groupI,2067 cm.sub.
[0231] Thus group I D-AA and group II D-AA concentrations can then be easily solved as:
[0232] Taking the average pixel intensity recording in
[c]group I1.06*(2067 cm.sup.1 signal)0.0047*(2133 cm.sup.1 signal),(1)
[c]group II(2133 cm.sup.1 signal)1.15*(2067 cm.sup.1 signal).(2)
Example 1d: SRS Imaging of Newly Synthesized Proteins in Live Mouse Brain Tissues
[0233] Going above the cellular level, we now apply our imaging platform to a more complex level, organotypical brain tissues. In our study, we focus on the hippocampus because it is the key region in brains that involves extensive protein synthesis. As expected, active protein synthesis is found in the hippocampal region, particularly in the dentate gyrus, which is known for its significant role in both long-term memory formation and adult neurogenesis. SRS image at 2133 cm.sup.1 (
[0234] In order to investigate spatial pattern of protein synthesis on a larger scale, we imaged the entire brain slice by acquiring large-area image mosaics. A 4-by-3 mm image (see
Example 1e: SRS Imaging of Newly Synthesized Proteins In Vivo
[0235] One prominent advantage of our labeling strategy is its non-toxicity and minimal invasiveness to animals. We thus move up to the physiological level to image protein metabolism in embryonic zebrafish and mice. Zebrafish are popular model organisms due to their well-understood genetics and transparent embryos, amenable to optical imaging. We injected 1 nL D-AA solution into zebrafish embryos at the 1-cell stage (150 ng D-AAs per embryo), and then allowed them to develop normally for 24 h (
[0236] Finally we demonstrate on mammalsmice. We administered the drinking water containing D-AAs to 3-week-old mice for 12 days, and then harvested liver and intestine tissues for subsequent imaging. No toxicity was observed for the fed mice. The SRS images from both live liver tissues (
[0237]
[0238]
Exemplary Physical Principle of Isotope-Based SRS Imaging
[0239] SRS microscopy can be a molecular-contrast, highly sensitive, imaging procedure with intrinsic 3D sectioning capability. It selectively images the distribution of molecules that carry a given type of chemical bonds through resonating with the specific vibrational frequency of the targeted bonds. (See, e.g., References 47, 54 and 65). As
[0240] The vibrational signal of C-D can be detected as an indicator for newly synthesized proteins that metabolically incorporate deuterium-labeled amino acids. (See, e.g.,
[0241] Imaging optimization by metabolic incorporation of deuterium-labeled all amino acids in live HeLa cells with multicolor SRS imaging. Although leucine can be the most abundant essential amino acid, it only accounts for a small fraction of amino acids in proteins. Thus, the deuterium labeling of all the amino acids can lead to a substantial signal enhancement. Indeed, the spontaneous Raman spectrum (e.g.,
Exemplary Time-Dependent De Novo Protein Synthesis and Protein Synthesis Inhibition
[0242] Being linearly dependent on analyte concentration, SRS contrast can be well suited for quantification of de novo protein synthesis in live cells. Here the time-dependent protein synthesis images can be shown under the same intensity scale. (See, e.g.,
[0243] The effect of protein synthesis inhibition by chemical drugs can be further tested to validate that the detected C-D signal indeed derives from nascent proteins. HeLa cells incubated with deuterium-labeled all amino acids together with 5 M anisomycin, which can work as a protein synthesis inhibitor by inhibiting peptidyl transferase or the 80S ribosome system, show the absence of the C-D signal in the spontaneous Raman spectrum. (See, e.g.,
Exemplary Demonstration On HEK293T Cells And Neuron-Like Differentiable Neuroblastoma N2A Cells
[0244] Two additional mammalian cell lines can be chosen for further demonstration: human embryonic kidney HEK293T cells, and neuron-like neuroblastoma mouse N2A cells, which can be induced to differentiate with the growth of neurites (e.g., axons and dendrites). The spontaneous Raman spectrum (e.g.,
[0245] In addition to showing the ability to image newly synthesized proteins inside cell body, the exemplary SRS can also be applied to tackle more complex problems, such as de novo protein synthesis in neuronal systems. (See, e.g., Reference 26-28). Under differentiation condition, N2A cells massively grow new neurites from cell bodies and form connections with other cells.
[0246] Hence, the neurites indicated by arrows can be most likely older than their starred counterparts. In addition, the transition from 3610 to 3605 in the merged image (e.g.,
Example 2: In Vitro and In Vivo Labeling with Alkyne Tags
Exemplary Methods and Materials
[0247] Bond-selective stimulated Raman scattering (SRS) microscopy.
[0248] Pump and Stokes beams are coupled into an inverted multiphoton laser-scanning microscope (FV1200MPE, Olympus) optimized for near-IR throughput. A 60 water objective (UPlanAPO/IR, 1.2 N.A., Olympus) with high near-IR transmission is used for all cell imaging. The pump/Stokes beam size is matched to fill the back-aperture of the objective. The forward going pump and Stokes beams after passing through the sample are collected in transmission with a high N.A. condenser lens (oil immersion, 1.4 N.A., Olympus) which is aligned following Kohler illumination. A telescope is then used to image the scanning mirrors onto a large area (10 by 10 mm) Si photodiode (FDS1010, Thorlabs) to descan beam motion during laser scanning. The photodiode is reverse biased by 64 V from a DC power supply to increase both the saturation threshold and response bandwidth. A high O.D. bandpass filter (890/220 CARS, Chroma Technology) is placed in front of the photodiode to block the Stokes beam completely and to transmit the pump beam only.
[0249] The output current of the photodiode is electronically pre-filtered by an 8-MHz band-pass filter (KR 2724, KR electronics) to suppress both the 80 MHz laser pulsing and the low-frequency fluctuations due to laser scanning cross the scattering sample. It is then fed into a radio frequency lock-in amplifier (SR844, Stanford Research Systems) terminated with 50 to demodulate the stimulated Raman loss signal experienced by the pump beam. The in-phase X-output of the lock-in amplifier is fed back into the analog interface box (FV10-ANALOG) of the microscope. The time constant is set for 10 s (the shortest available with no additional filter applied). The current SRS imaging speed is limited by the shortest time constant available from the lock-in amplifier (SR844). For all imaging, 512 by 512 pixels are acquired for one frame with a 100 s of pixel dwell time (26 s per frame) for laser scanning and 10 s of time constant from the lock-in amplifier. Laser powers after 60 IR objective used for imaging are: 130 mW for modulated Stokes beam; 120 mW for the pump beam in 2133 cm.sup.1, 2142 cm.sup.1, 2000 cm.sup.1 and 1655 cm.sup.1 channels, 85 mW for the pump beam in 2230 cm.sup.1 and 2300 cm.sup.1 channels, and 50 mW for pump beam in 2845 cm.sup.1 channels.
[0250] Spontaneous Raman Spectroscopy. The spontaneous Raman spectra were acquired using a laser confocal Raman microscope (Xplora, Horiba Jobin Yvon) at room temperature. A 12 mW (after the microscope objective), 532 nm diode laser was used to excite the sample through a 50, N.A.=0.75 air objective (MPlan N, Olympus). The total data acquisition time was 300 s using the LabSpec 6 software. All the spontaneous Raman spectra have subtracted the PBS solution background.
[0251] Materials. 5-Ethynyl-2-deoxyuridine (EdU) (T511285), 17-Octadecynoic acid (17-ODYA) (08382), DMEM medium without L-methionine, L-cysteine and L-glutamine (D0422), L-methionine (M5308), L-cysteine (C7602), 2-Mercaptoethanol (M3148) and Phorbol 12-myristate 13-acetate (P1585) were purchased from Sigma-Aldrich. 5-Ethynyl Uridine (EU) (E-10345), Homopropargylglycine (Hpg) (C10186), Alexa Fluor 488 Azide (A10266), Click-iT Cell Reaction Buffer Kit (C10269), DMEM medium (11965), FBS (10082), penicillin/streptomycin (15140), L-glutamine (25030), Neurobasal A Medium (10888) and B27 supplement (17504) were purchased from Invitrogen. RPMI-1640 Medium (30-2001) was purchased from ATCC. BCS (hyclone SH30072) was purchased from Fisher Scientific.
[0252] DMEM culture medium was made by adding 10% (vol/vol) FBS and 1% (vol/vol) penicillin/streptomycin to the DMEM medium. Methionine-deficient culture medium was made by supplying 4 mM L-glutamine, 0.2 mM L-cysteine, 10% FBS and 1% penicillin/streptomycin to the DMEM medium without L-methionine, L-cysteine and L-glutamine. RPMI-1640 culture medium was made of supplying the RPMI-1640 medium with 10% FBS, 1% penicillin/streptomycin and 50 M 2-Mercaptoethanol. Neuron culture medium was made of Neurobasal A Medium adding with 1B27 supplement and 0.5 mM glutamine. Culture medium for NIH3T3 cells was made by adding 10% (vol/vol) BCS and 1% (vol/vol) penicillin/streptomycin to the DMEM medium.
[0253] Propargylcholine synthesis. Propargylcholine was synthesized according to Jao, C. Y., Roth, M., Welti, R. & Salic, A. Proc. Natl. Acad. Sci. USA 106, 15332-15337 (2009). 3 mL propargyl bromide (80 wt. % solution in toluene) were added dropwise to 3 g 2-dimethylaminoethanol in 10 mL anhydrous THF on ice under argon gas protection and stirring. The ice bath was removed and the mixture was kept stirring at room temperature overnight. The white solids were filtered the next day and washed extensively with cold anhydrous THF to obtain 5 g pure propargylcholine bromide. All chemicals here are purchased from Sigma-Aldrich. NMR spectrum was recorded on a Bruker 400 (400 MHz) Fourier Transform (FT) NMR spectrometers at the Columbia University Chemistry Department. .sup.1H NMR spectra are tabulated in the following order: multiplicity (s, singlet; d, doublet; t, triplet; m, multiplet), number of protons. .sup.1H NMR (400 MHz, D.sub.2O) ppm: 4.37 (d, J=2.4 Hz, 2H); 4.10 (m, 2H); 3.66 (t, J=4.8 Hz, 2H); 3.28 (s, 6H); MS (APCI+) m/z Calcd. for C.sub.7H.sub.14NO [M].sup.+:128.19. Found: 128.26.
[0254] Sample preparation for SRS imaging of live cells and organisms. For all SRS imaging experiments of HeLa cells (e.g.
[0259] For the propargylcholine experiment in neurons, hippocampal neurons were cultured on coverslips in 1 ml neuron culture medium for 14 d, and then propargylcholine (25 mM stock in PBS) is directly added into the medium to a final concentration of 1 mM for 24 h.
[0260] For the 17-ODYA experiment in macrophages, THP-1 cells were first Seeded on coverslips at a density of 2105/mL in 2 ml RPMI-1640 culture medium for 24 h, followed by 72 h induction of differentiation to macrophages by incubating with 100 ng/ml Phorbol 12-myristate 13-acetate (PMA) in the medium. Medium was then replaced with RPMI-1640 culture medium containing 400 M 17-ODYA (6:1 complexed to BSA) for 15 h.
[0261] For all of the above experiments, after incubation, the coverslip is taken out to make an imaging chamber filled with PBS for SRS imaging.
[0262] For the 17-ODYA experiment in C. elegans, OP50 bacterial culture was mixed well with 4 mM 17-ODYA (from 100 mM ethanol stock solution), and then Seeded onto nematode growth media (NGM) plates. After drying the plates in hood, wild type N2 day 1 adult C. elegans were placed onto the plates and fed for 40 h. C. elegans were then mounted on 2% agarose pads containing 0.1% NaN.sub.3 as anesthetic on glass microscope slides for SRS imaging.
[0263] SRS imaging of C. elegans germline after feeding with EdU. MG1693 (thymidine defective MG1655) E. Coli strain was cultured in 2 ml LB medium at 37 C. overnight, and transferred to 100 ml of M9 medium containing 400 M EdU for further growth at 37 C. for 24 h. The EdU-labeled MG1693 E. Coli was then Seeded on M9 agar plate. Synchronized day 1 adult worms developed in 20 C. were transferred to EdU-labeled bacterial plate for 3 h, and then were dissected to take out the germline for imaging (e.g.
[0264] Cell preparation for click chemistry-based fluorescence microscopy. All experiments (e.g.
[0265] Enzymatic assays confirming propargylcholine incorporation into cellular choline phospholipids. We design our control experiments according to the click chemistry based assays reported in Jao, C. Y., Roth, M., Welti, R. & Salic, A. Proc. Natl. Acad. Sci. USA 106, 15332-15337 (2009) (e.g.
[0266] Sample preparation for drug delivery into mouse ear tissues. Either DMSO solution or Drug cream (Lamisil, Novartis) containing 1% (w/w) active terbinafine hydrochloride (TH) was applied to the ears of an anesthetized live mouse (2-3 weeks old white mouse of either sex) for 30 min, and the dissected ears from the sacrificed mouse were then imaged by SRS (e.g.
[0267] Image progressing. Images are acquired with FluoView scanning software and assigned color or overlaid by ImageJ. Graphs were assembled with Adobe Illustrator.
Example 2a: Alkyne Tags
[0268] As an effective imaging modality for small biomolecules, we report a general strategy of using stimulated Raman scattering (SRS) microscopy to image alkynes (i.e., CC) as nonlinear vibrational tags, shown as bond-selective SRS in
[0269] The coupling of SRS microscopy to alkyne tags that we report offers sensitivity, specificity and biocompatibility for probing complex living systems. When the energy difference between incident photons from two lasers (pump and Stokes) matches with the 2125 cm.sup.1 mode of alkyne vibrations, their joint action will greatly accelerate the vibrational excitation of alkyne bonds. As a result of energy exchange between the input photons and alkynes, the output pump and Stokes beams will experience intensity loss and gain, respectively. Such intensity changes measured by SRS microscopy generate concentration-dependent alkyne distributions in three-dimensions (3D).
[0270] SRS microscopy offers a number of advantages. First, SRS boosts vibrational excitation by a factor of 107, rendering a quantum leap of sensitivity (i.e., detectability and speed) over spontaneous Raman. Second, we use a 6-ps pulse width to match the excitation profile of alkyne (e.g.
[0271] We first detected the alkyne-tagged thymidine analogue 5-ethynyl-2-deoxyuridine (EdU) in solution (e.g.
[0272] We imaged the metabolic uptake of EdU during de novo DNA synthesis. HeLa cells grown in media with EdU show a sharp Raman peak at 2125 cm.sup.1 in the cell-silent region (e.g.
[0273] Next, we studied RNA transcription and turnover using the alkyne-tagged uridine analogue, 5-ethynyl uridine (EU).sup.8 in HeLa cells (e.g.
[0274] Many intricate biological processes such as long-term memory require protein synthesis in a spatiotemporal dependent manner. We imaged L-Homopropargylglycine (Hpg), an alkyne-tagged analogue of methionine, to visualize newly synthesized proteomes. HeLa cells grown in methionine-deficient media supplemented with Hpg display an alkyne peak (e.g.
[0275] Lipid metabolism is critical for many functions in healthy and diseased tissues, but few non-perturbative tags are available to monitor lipids in the cell. We thus monitored the metabolic incorporation of alkyne-tagged choline and fatty acids. Hippocampal neurons grown on propargylcholine present a clear 2142 cm.sup.1 Raman peak (e.g.
[0276] Finally, we tracked alkyne-bearing drug delivery (
[0277]
[0278]
[0279] Unlike bulky fluorophores, alkynes have little perturbation to pharmacokinetics and are common moieties in many pharmaceuticals. We chose terbinafine hydrochloride (TH), a US Federal Drug Administration approved alkyne-bearing antifungal skin drug, and imaged its drug delivery pathways inside mouse ear tissue to a depth of about 100 m by targeting its internal alkyne at 2230 cm.sup.1. TH images captured at various depths all exhibit patterns that highly resemble lipid distributions but not protein distributions, suggesting that TH penetrates into tissues through the lipid phase, consistent with its lipophilic nature. Our technique should be applicable to tracking other drugs after proper alkyne derivatization.
[0280] In conclusion, we report a general strategy to image small and biologically vital molecules in live cells by coupling SRS microscopy with alkyne vibrational tags. The major advantages of SRS lie in the superior sensitivity, specificity and compatibility with dynamics of live cells and animals. SRS imaging of alkynes may do for small biomolecules what fluorescence imaging of fluorophores has done for larger species.
Example 3: Synthesis of Bond-Edited Compounds
[0281] A. Synthesis of Alkyne-D-Glucose
##STR00015##
[0282] Sodium hydride (138 mg, 5.8 mmol) was added to a solution of 1,2:5,6-Di-O-isopropylidene--D-glucofuranose (Compound S1, 500 mg, 1.92 mmol, Aldrich D7600) in 10 mL dry DMF at 0 C. The solution was stirred at 0 C. for 30 min before propargyl bromide (80% in toluene, 0.43 mL, 3.84 mmol) was added dropwise. The reaction mixture was stirred at room temperature for 12 h before quenched with saturated ammonium chloride solution (10 mL). The mixture was extracted with ethyl acetate (225 mL), and the organic layer was combined, dried over anhydrous sodium sulfate, concentrated in vacuo, and purified by column chromatography on silica gel (0-50% Ethyl acetate in Hexanes) to give Compound S2 (518 mg, 90%) as a colorless oil. The .sup.1H NMR spectrum is in accordance with previously published values (A. Hausherr et al., Synthesis, 2001, 1377).
[0283] .sup.1H NMR (400 MHz, CDCl.sub.3) 5.88 (d, J=3.6 Hz, 1H), 4.30-4.24 (m, 3H), 4.14 (dd, J=7.6, 2.8 Hz, 1H), 4.11-4.06 (m, 2H), 3.99 (dd, J=8.8, 5.6 Hz, 1H), 2.47 (t, J=2.4 Hz, 1H), 1.50 (s, 3H), 1.42 (s, 3H), 1.35 (s, 3H), 1.31 (s, 3H).
[0284] HRMS (FAB+) m/z Calcd. for C.sub.15H.sub.23O.sub.6 [M+H].sup.+: 299.1495. Found: 299.1496
##STR00016##
[0285] Water (10 mL) and Dowex 50WX8 hydrogen form (600 mg, Sigma-Aldrich 217514) were added to Compound S2 (594 mg, 1.99 mmol). The mixture was heated to 80 C. for 20 h before filtered. The filtrate was concentrated in vacuo to give Compound S3 (416 mg, 1.91 mmol, 96%) as a white solid.
[0286] .sup.1H NMR (400 MHz, D.sub.2O) 5.13 (d, J=3.6 Hz, 1H), 4.44 (d, J=2.4 Hz, 2H), 3.79-3.73 (m, 2H), 3.70-3.61 (m, 2H), 3.51 (dd, J=9.8, 3.8 Hz 1H), 3.40 (t, J=9.6 Hz, 11H), 2.82 (s, 1H). .sup.13C NMR (101 MHz, D.sub.2O) 92.1, 80.8, 79.8, 75.9, 71.4, 71.2, 69.2, 60.4, 59.9.
[0287] HRMS (FAB+) m/z Calcd. for C.sub.9H.sub.14O.sub.6Na [M+Na]+: 241.0688. Found: 241.0683
[0288] B. Synthesis of EdU-.sup.13C (Compound 2) and EdU-.sup.13C.sub.2 (Compound 3)
##STR00017##
[0289] Synthesis of Compound 4:
##STR00018##
[0290] To a solution of 5-iodo-2-deoxyuridine (Compound 1, 150 mg, 0.42 mmol) in 1.5 ml of pyridine was added 0.4 ml (0.42 mmol) acetic anhydride at 0 C. The resulting mixture was warmed up to room temperature and stirred for 4 h, then poured into 5 ml of cold 1N NaHSO.sub.4 and extracted with ethyl acetate three times. The organic layer was washed with saturated NaHCO.sub.3 and brine, dried over anhydrous Na.sub.2SO.sub.4 and concentrated. The crude product was purified by column chromatography on silica gel (0-70% Ethyl acetate in Hexanes) to give Compound 4 (157.3 mg, 0.36 mmol, 85%) as a white solid.
[0291] .sup.1H NMR (400 MHz, CDCl.sub.3) ppm: 8.46 (s, 1H), 7.97 (s, 1H), 6.28 (dd, J=8.2, 5.7 Hz, 1H), 5.27-5.19 (m, 1H), 4.41 (dd, J=12.3, 3.2 Hz, 1H), 4.34 (dd, J=12.3, 2.9 Hz, 1H), 4.30 (q, J=2.9 Hz, 1H), 2.54 (ddd, J=14.3, 5.7, 2.1 Hz, 1H), 2.21 (s, 3H), 2.20-2.13 (m, 1H), 2.12 (s, 3H).
[0292] MS (APCI+) m/z Calcd. for C13H.sub.16IN.sub.2O.sub.7 [M+H].sup.+: 439.0. Found: 438.8
Synthesis of Compound 5:
[0293] ##STR00019##
[0294] To an oven-dried vial was added Compound 4 (72 mg, 164 mol), Pd(OAc).sub.2 (3.6 mg, 16 mol), PPh.sub.3 (8.6 mg, 33 mol), CuI (3.1 mg, 16 mol), DMF (2 ml), Et3N (50 mg, 69 l, 492 mol) and TMS.sup.13C.sup.13CH (25 mg, 250 mol) under Ar. The yellow mixture was stirred at RT for 15 h before concentrated in vacuo. The residue was purified by column chromatography on silica gel (0-70% Ethyl acetate in Hexanes) to give Compound 5 (48.4 mg, 118 mol, 72%) as a thin film.
[0295] .sup.1H NMR (400 MHz, Methanol-d4) 7.98 (d, J=5.0 Hz, 1H), 6.23 (dd, J=7.8, 6.0 Hz, 1H), 5.28 (dt, J=6.7, 2.6 Hz, 1H), 4.36 (t, J=3.1 Hz, 2H), 4.34-4.28 (m, 1H), 2.50 (ddd, J=14.5, 6.0, 2.5 Hz, 1H), 2.39 (ddd, J=14.5, 7.9, 6.6 Hz, 1H), 2.16 (s, 3H), 2.09 (s, 3H), 0.20 (d, J=2.5 Hz, 9H). .sup.13C NMR (101 MHz, MeOD) 99.54 (d, J=140.5 Hz), 96.95 (d, J=140.5 Hz).
[0296] MS (APCI+) m/z Calcd. for C.sub.16.sup.13C.sub.2H.sub.25N.sub.2O.sub.7Si [M+H]+: 411.2. Found: 411.0
Synthesis of Compound 3:
[0297] ##STR00020##
[0298] To a solution of Compound 5 (3.5 mg, 8.5 mol) in 0.9 ml MeOH and 0.1 ml H.sub.2O was added K.sub.2CO.sub.3 (6.0 mg, 43 mol) at RT. The reaction was stirred overnight before concentrated in vacuo. The residue was purified by reverse phase HPLC to give compound 3 (1.6 mg, 6.4 mol, 75%) as a thin film.
[0299] HPLC condition: 20 min gradient elution using H.sub.2O:MeCN starting from 100:0 to 85:15. Retention time: 15.4 min
[0300] .sup.1H NMR (400 MHz, MeOD) : 8.39 (d, J=5.6 Hz, 1H); 6.24 (t, J=6.4 Hz, 1H); 4.40 (m, 1H); 3.94 (dd, J=6.4, 3.2 Hz, 1H); 3.82 (dd, J=12, 3.2 Hz, 1H); 3.73 (dd, J=12, 3.6 Hz, 1H); 3.53 (dd, J=250.4, 54.8 Hz, 1H); 2.32 (ddd, J=13.6, 6, 3.6 Hz, 1H); 2.23 (m, 1H). .sup.13C NMR (101 MHz, MeOD) 82.87 (d, J=180.4 Hz), 75.85 (d, J=180.3 Hz).
[0301] MS (FAB+) m/z Calcd. for C.sub.9.sup.13C.sub.2H.sub.13N.sub.2O.sub.5 [M+H].sup.+: 255.09. Found: 255.11
Synthesis of Compound 9:
[0302] ##STR00021##
[0303] To a solution of ethynylmagnesium bromide in THF (5.0 ml, 0.5 M solution, 2.5 mmol) was added 15 ml THF under Ar. The solution was cooled to 78 C. and 2.4 ml n-BuLi in hexane (1.6 M, 3.8 mmol) was added dropwisely. After 30 min, chloro(dimethyl)octylsilane (1.21 ml, 1.06 g, 5.1 mmol) was added dropwisely. The reaction was then warmed to RT and stirred for another 3 h before filtered through a short pad of silica. The solvent was removed under reduced pressure and the residue was purified by column chromatography on silica gel (pure Hexanes) to give Compound 9 (885 mg, 2.4 mmol, 96%) as a colorless liquid.
[0304] .sup.1H NMR (400 MHz, Chloroform-d) 1.42-1.24 (m, 24H), 0.88 (t, J=6.6 Hz, 6H), 0.60 (dd, J=9.4, 6.2 Hz, 4H), 0.13 (s, 12H). .sup.13C NMR (101 MHz, Chloroform-d) 113.94, 33.37, 32.12, 29.49, 29.43, 23.92, 22.85, 16.26, 14.27, 1.55.
[0305] HRMS (EI+) m/z Calcd. for C.sub.22H.sub.46Si.sub.2 [M].sup.+:366.3138. Found: 366.3134
Synthesis of Compound 10:
[0306] ##STR00022##
[0307] In a glove box filled with Ar, catalyst 8 (36.5 mol, 5 eq.) was prepared in 0.5 mL dry CCl4 in situ according to the procedure documented by Jyothish and Zhang (Angew. Chem. Int. Ed. Engl. 50, 3435-8 (2011)). To the solution of catalyst 8 in CCl4 was added 9 (267 mg, 0.73 mmol) and a solution of Compound 5 (3.0 mg, 7.3 mol) in 0.5 mL dry CCl4. The mixture was heated to 70 C. for 8 h before concentrated in vacuo. The residue was purified by column chromatography on silica gel (0-70% Ethyl acetate in Hexanes) to recover Compound 5 (0.5 mg, 1.2 mol) and to give Compound 10 (1.0 mg, 2.0 mol, 27%, 33% B.R.S.M.) as a thin film.
[0308] .sup.1H NMR (400 MHz, Methanol-d4) 7.97 (d, J=5.6 Hz, 1H), 6.23 (dd, J=7.9, 5.9 Hz, 1H), 5.28 (dt, J=6.8, 2.4 Hz, 1H), 4.36 (dd, J=5.8, 3.4 Hz, 2H), 4.31 (dd, J=6.3, 3.2 Hz, 1H), 2.50 (ddd, J=14.5, 6.1, 2.5 Hz, 1H), 2.38 (ddd, J=20.2, 7.7, 6.1 Hz, 1H), 2.15 (s, 3H), 2.09 (s, 3H), 1.30 (s, 12H), 0.90 (t, J=6.9 Hz, 3H), 0.70-0.62 (m, 2H), 0.18 (s, 6H). .sup.13C NMR (101 MHz, MeOD) 97.56.
[0309] MS (FAB+) m/z Calcd. for C.sub.24.sup.13CH.sub.38N.sub.2NaO.sub.7Si [M+Na]+: 530.24. Found: 530.25
Synthesis of Compound 2:
[0310] ##STR00023##
[0311] To a solution of compound 10 (0.4 mg, 0.8 mol) in 0.5 ml MeOH and 0.05 ml H.sub.2O was added K.sub.2CO.sub.3 (2.0 mg, 14 mol) and TBAF (20 L, 1 M in THF) at RT. The reaction was stirred 7 h at RT before concentrated in vacuo. The residue was purified by reverse phase HPLC to give compound 2 (0.1 mg, 0.4 mol, 50%) as a thin film.
[0312] HPLC condition: 20 min gradient elution using H.sub.2O:MeCN starting from 100:0 to 85:15. Retention time: 15.4 min
[0313] The mass of the product is determined by UV-Vis (abs=288 nm, =12,000 cm.sup.1 M-1 in methanol).
[0314] .sup.1H NMR (500 MHz, Methanol-d4) 8.39 (d, J=5.7 Hz, 1H), 6.24 (t, J=6.5 Hz, 1H), 4.40 (dt, J=6.6, 3.6 Hz, 1H), 3.94 (q, J=3.3 Hz, 1H), 3.82 (dd, J=12.0, 3.1 Hz, 1H), 3.73 (dd, J=12.0, 3.4 Hz, 1H), 3.53 (d, J=51.3 Hz, 1H), 2.32 (ddd, J=13.6, 6.2, 3.7 Hz, 1H), 2.27-2.17 (m, 1H). .sup.13C NMR (101 MHz, MeOD) 76.00. MS (ESI+) m/z Calcd. for C.sub.10.sup.13CH.sub.13N.sub.2O.sub.5 [M+H]+: 254.09. Found: 254.70
Synthesis of EU-.SUP.13.C2 (Compound 13)
[0315] ##STR00024##
[0316] To an oven-dried vial was added compound S5 (15 mg, 50 mol), Pd(OAc)2 (1.1 mg, 5 mol), PPh3 (2.6 mg, 10 mol) CuI (1.0 mg, 5 mol), DMF (1 ml), Et3N (15 mg, 20.7 l, 150 umol) and TMS.sup.13C.sup.13CH (7.5 mg, 10.8 l, 75 mol) under Ar. The mixture was stirred at RT for 12 h before concentrated in vacuo. The residue was purified by column chromatography on silica gel (0-50% methanol in dichloromethane) to give compound S6 (9.0 mg, 26 mol, 52%) as a thin film.
[0317] .sup.1H NMR (400 MHz, Methanol-d4) 8.41 (d, J=4.9 Hz, 1H), 5.91-5.83 (m, 1H), 4.21-4.13 (m, 2H), 4.07-3.98 (m, 1H), 3.88 (dd, J=12.2, 2.6 Hz, 1H), 3.75 (dd, J=12.2, 2.8 Hz, 1H), 0.20 (d, J=2.3 Hz, 9H). .sup.13C NMR (101 MHz, MeOD) 99.24 (d, J=141.0 Hz), 96.95 (d, J=141.0 Hz).
[0318] MS (FAB+) m/z Calcd. for C.sub.12.sup.13C.sub.2H.sub.21N.sub.2O.sub.6Si [M+H]+: 343.12. Found: 343.17.
Synthesis of Compound 13:
[0319] ##STR00025##
[0320] To a solution of compound S6 (3.0 mg, 8.8 mol) in 0.6 ml MeOH and 0.1 ml H.sub.2O was added K.sub.2CO.sub.3 (5.0 mg, 36 mol) at RT. The reaction was stirred overnight before concentrated in vacuo. The residue was purified by reverse phase HPLC to give compound 13 (2.2 mg, 8.1 mol, 92%) as a thin film.
[0321] .sup.1H NMR (400 MHz, Methanol-d4) 8.47 (d, J=5.6 Hz, 1H), 5.93-5.83 (m, 1H), 4.21-4.13 (m, 2H), 4.06-3.98 (m, 1H), 3.88 (dd, J=12.2, 2.6 Hz, 1H), 3.75 (dd, J=12.2, 2.8 Hz, 1H), 3.54 (dd, J=250.4, 54.6 Hz). .sup.13C NMR (101 MHz, MeOD) 82.90 (d, J=180.2 Hz), 75.74 (d, J=180.2 Hz).
[0322] MS (ESI+) m/z Calcd. for C.sub.9.sup.13C.sub.2H.sub.13N.sub.2O.sub.6 [M+H]+: 271.08. Found: 271.51
[0323]
[0324] As shown in
[0325] Further, the exemplary processing arrangement 3802 can be provided with or include an input/output arrangement 3814, which can include, for example a wired network, a wireless network, the internet, an intranet, a data collection probe, a sensor, etc. As shown in
Exemplary Imaging Intracellular Fluorophores with Sub-Micromolar Sensitivity Using Pre-Resonance Stimulated Raman Scattering
[0326] The exemplary system, method and computer-accessible medium, according to an exemplary embodiment of the present disclosure, can utilize pr-SRS microscopy and apply such exemplary procedure to image molecules in the pre-resonance Raman regime to achieve both superb sensitivity at sub-micromolar concentration, and chemical specificity for multiplex imaging (see, e.g.,
.sub.st=.sub.spG(p.sub.w.sub.
where G(p.sub.w.sub.
[0327] However, current SRS sensitivity can still be far from that of fluorescence microscopy. The measured SRS detection limit of a typical chemical bond such as carbon-hydrogen bond (CH, .sub.sp10.sup.30 cm.sup.2) can be about 15 mM. (See, e.g., Reference 99). Even for chemical bonds with exceptional strong Raman polarizability, such as alkynes (CC), the reported detection limit can be about 200 M. (See, e.g., Reference 103). Efforts have been devoted to synthesize molecules with stronger Raman vibration, however, only a few molecules present such property, and the improvements can typically only be about 27 times. (See, e.g., Reference 104). Presently, all the SRS applications focus on probing molecules in the non-resonance region where the absorption peak energy (0) of the molecules can be much larger than the pump laser energy (pump). (See, e.g.,
.sub.sp,RE=.sub.spG.sub.RE(2a)
where, G.sub.RE can be the resonance enhanced Raman gain factor, which can increase when the energy difference between 0 and pump can decrease. Furthermore, the effective resonance enhanced SRS cross-section can be expressed as, for example:
.sub.st,RE=.sub.spG.sub.REG(p.sub.w.sub.
[0328] To illustrate the resonance Raman enhancement in the nonlinear SRS microscopy, for example, a non-resonance SRS spectrum of Coumarin 153 can be measured, which can show an absorption peak wavelength (max) at about 422 nm (e.g., 23697 cm.sup.1, 0>>pump) (see, e.g.,
[0329] Close inspection for both the non-resonance SRS spectrum of Coumarin 153 (see, e.g.,
[0330] An exemplary configuration and principle for pre-resonance SRS microscopy according to an exemplary embodiment of the present disclosure, is shown in
[0331] To illustrate further the pr-SRS enhancement between the experiment results and theory,
where vib can be the vibrational transition energy. Based on the above, it was determined that the pre-resonance enhancement from theoretical calculations can match very well with the experimental results. The grey shaded area 4005 from
[0332] With such sensitivity, both high sensitivity and chemical specificity for the exemplary pr-SRS technique in solutions can be analyzed. By appropriately selecting the imaging condition with excitation power that can be low enough not to damage the fluorophore but high enough to mildly saturate the Raman transition of ATTO740, the measured detection limit with shot-noise limited sensitivity for ATTO740 can be about 0.7 M with about a 1 ms time constant and about a 2 M with about a 100 s time constant that can be suitable for live-cell imaging (see, e.g.,
[0333]
[0334] Pr-SRS imaging on intracellular fluorophores can be provided which have achieved exceptional image contrast with a panel of immuno-labeled specific types of intracellular proteins including tubulin, Tom20 (e.g., mitochondria marker), giantin (e.g., Golgi marker) and neurofilament heavy proteins (e.g., Neuronal Marker) with ATTO740 and Dylight650 dyes in either cultured hippocampal neurons or HeLa cells. (See, e.g.,
[0335] Indeed,
[0336] Thus, from both the spectroscopy and imaging perspectives, the superb sensitivity and the distinct chemical specificity for the exemplary pr-SRS of fluorophores is shown. With such sensitivity and specificity, the uses of the exemplary system, method and computer-accessible medium for biomedical researches, among which large number multi-color imaging can be important. For example,
[0337] In particular,
[0338] Additional exemplary labels can be created for pr-SRS palette using various other vibrational moieties. Unlike CC, which can exhibit multiple peaks in the crowded fingerprint region, triple bonds, including alkyne or nitrile, can display a single sharp Raman peak in the wide silent window (e.g., from about 1800 to about 2800 cm.sup.1) free from cellular background. Thus pr-SRS imaging of triple bonds can greatly expand a vibrational palette with minimum cross talks. This can be non-trivial because triple bonds may need to be coupled with an electronic transition in order to gain resonance enhancement. Thus, described herein is a new family of vibrational dyes in which triple bonds can directly participate in the -conjugation systems. For example, general dye scaffolds with optimal conjugation position of triple bonds were determined, and then their absorption peaks were tuned into the pr-SRS region, ensuring both intensity and chemical specificity. To generate more vibrational colors, an isotopic edition on the triple bonds was utilized in conjunction with exquisite electron-density tuning on the -conjugation system to shift the peak frequency. The resulting 10 exemplary reporters, termed Manhattan Raman scattering (MARS) dyes (see e.g.,
[0339] Additionally, the exemplary system, method and computer-accessible medium, according to an exemplary embodiment of the present disclosure, can utilize pr-SRS that can achieve an increased detection sensitivity down to sub-micromole and high chemical specificity for multicolor imaging. For example, a narrow region of the absorption peaks of dyes can be selected that can be suitable for pr-SRS imaging, which can benefit from pre-resonance Raman enhancement, but does not suffer from any other competing pump-probe signal contributing to a large off-resonance background. With such sensitivity and specificity, 4-color imaging can be achieved by commercially available dyes with pr-SRS alone, which can already be comparable to the typical number limit in multi-color fluorescence imaging. In tandem with fluorescence microscopy, simultaneous imaging of 3 more colors can be obtained, thus, almost doubling the number limit of multicolor fluorescence imaging. This number can be expanded furthermore with custom synthesized molecules leading to more resolvable pr-SRS colors.
Exemplary SI Methods and Materials
[0340] An integrated laser (e.g., picoEMERALD with custom modification, Applied Physics & Electronics, Inc.) can be used as the light source for both pump and Stokes beams. picoEMERALD can provide an output pulse train at 1064 nm with 6 ps pulse width and 80 MHz repetition rate, which serves as the Stokes beam. The frequency-doubled beam at 532 nm can be used to synchronously seed a picosecond optical parametric oscillator (OPO) to produce a mode-locked pulse train (e.g., the idler beam of the OPO can be blocked with an interferometric filter) with 56 ps pulse width. The wavelength of the OPO can be tunable from about 720 to about 990 nm, which can serve as the pump beam. The intensity of the about 1064 nm Stokes beam can be modulated sinusoidally by a built-in electro-optic modulator (EOM) at about 8 MHz with a modulation depth of more than about 95%. The pump beam can be spatially overlapped with the Stokes beam with a dichroic mirror inside picoEMERALD. The temporal overlap between pump and Stokes pulse trains can be ensured with a built-in delay stage and optimized by the SRS signal of pure dodecane liquid.
[0341] Pump and Stokes beams can be coupled into an inverted laser-scanning microscope (e.g., FV1200MPE, Olympus) optimized for near IR throughput. An about 60 water objective (UPlanAPO/IR, 1.2 N.A., Olympus) with high near IR transmission can be used for all cellular level imaging, and a 25 water objective (XLPlan N, 1.05 N.A., MP, Olympus) with both high near IR transmission and a large field of view can be used for brain tissue and in vivo imaging. The Pump/Stokes beam size can be matched to fill the back-aperture of the objective. The forward going Pump and Stokes beams, after passing through the sample, can be collected in transmission with a high N.A. condenser lens (e.g., oil immersion, 1.4 N.A., Olympus), which can be aligned following Kohler illumination. A telescope can then be used to image the scanning mirrors onto a large area (e.g., about 10 mm by about 10 mm) Si photodiode (e.g., FDS1010, Thorlabs) to descan beam motion during laser scanning. The photodiode can be reverse-biased by about 64 V from a DC power supply to increase both the saturation threshold and response bandwidth.
[0342] A high optical density (O.D.) bandpass filter (e.g., 890/220 CARS, Chroma Technology) can be used to block the Stokes beam completely, and transmit the Pump beam only. The output current of the photodiode can be electronically pre-filtered by an about 8-MHz band-pass filter (e.g., KR 2724, KR electronics) to suppress both the 80 MHz laser pulsing and the low-frequency contribution due to laser scanning across the scattering sample. It can then be fed into a radio frequency lock-in amplifier (e.g., SR844, Stanford Research Systems) terminated with about 50 to demodulate the stimulated Raman loss signal experienced by the pump beam. The in-phase X-output of the lock-in amplifier can be fed back into the analog interface box (e.g., FV10-ANALOG) of the microscope. For all imaging, about 256 by 256 pixels can be acquired for one frame with an about 200 s of pixel dwell time (e.g., 13 s per frame) for laser scanning and about 100 s of time constant (e.g., 6 db filter) from the lock-in amplifier. For
Exemplary SRS Spectra
[0343] Stimulated Raman scattering spectra for all fluorophores can be acquired by fixing the stokes beam laser at about 1064.2 nm, and scanning the pump laser through a designated wavelength range point by point.
Exemplary Materials
[0344] Fluorophores can include, for example: 5-Ethynyl-2-deoxyuridine (T511285, Aldrich); L-Azidohomoalanine (AHA) (C10102, Invitrogen), Click-iT Cell Reaction Buffer Kit (C10269, Invitrogen).
[0345] Fluorophores for SRS in
[0346] Other Fluorophores can include: IR895 (392375 Sigma, max895 nm); MitoTracker Orange CMTMRos (M-7510, Invitrogen); NucBlue Fixed Cell ReadyProbes Reagent (DAPI) (R37606, Invitrogen).
[0347] Primary antibodies can include: Anti-Fibrillarin antibodyNucleolar Marker (ab5821, Abcam); Anti-200 kD Neurofilament Heavy antibody (ab4680, Abcam); Anti-a-Tubulin antibody (T9026, Sigma); Anti-Giantin antibody (ab24586, Abcam); Anti-Tom20 Antibody (sc-11415, Santa Cruz Biotechnology); Anti-Calnexin antibodyER Membrane Marker (ab140818, Abcam).
[0348] Secondary antibodies conjugated with fluorophores can include, e.g.: Goat-anti-Rabbit IgG-Atto 740 antibody (49559, Sigma); Goat-anti-Mouse IgG-Atto 700 antibody (2110, Hypermol); Goat anti-Chicken IgY DyLight 488 antibody (SA5-10070, Thermo Scientific).
Exemplary Sample Preparation for Intracellular Cell Imaging
[0349] For immuno-staining cells can be fixed in methanol for about 28 min or first in about 4% PFA for about 8 min and then replaced with methanol for about 20 min more. Cells can then be washed with about 10% goat serum/1% BSA/0.3 M glycine solution twice before permealization in about 0.01% triton PBS for about 45 min. Primary antibody can then be added with about 1:200 dilution in about 3% BSA in 4 C overnight. After blocking with about 10% goat serum for about 30 min, secondary antibody conjugated with fluorophores can be added with about 1:100 dilution in about 10% goat serum in 4 C overnight.
[0350] For 7-color pr-SRS and fluorescence tandem imaging, HeLa cells can be seeded on a coverslip in a petri-dish with about 2 mL of DMEM for about 20 h, and then replaced with Methionine-deficient medium for about 30 min. Then about 1 mM AHA and about 100 M EdU can be added in to medium for about 18 hr. An about 400 nM MitoTracker Orange can be added into medium for about 30 min before fixation of the cell with about 4% PFA for about 8 min and then replaced with methanol for about 20 min more. Immuno-staining follows the procedure above. After immuno-staining, about 4 M Cy5.5-azide can be added to the cells with click-it Cell Reaction Buffer for the reaction with EdU following the manual from Invitrogen. After washing with PBS, about 4 M alexa647-alkyne can be added to the cells with click-it Cell Reaction Buffer for the reaction with AHA. At last, DAPI can be added to cells for 20 min following the instruction from manual.
[0351] DMEM was made of about 90% DMEM medium (e.g., 11965, Invitrogen), about 10% FBS (e.g., 10082, Invitrogen) and about 1 penicillin/streptomycin (e.g., 15140, Invitrogen); Methionine-deficient medium was made by supplying about 4 mM L-glutamine, about 0.2 mM L-cysteine, about 10% FBS and about 1% penicillin/streptomycin to the DMEM medium without L-methionine, L-cysteine and L-glutamine.
Exemplary Linear Combination Procedure
[0352] Because the exemplary SRS signal can be linearly dependent on the analyte concentration, the 4-channel pr-SRS signal for the concentrations of the ATTO740 labeled nucleoli Fibrillarin protein, ATTO700 labeled u-tubulin, Cy5.5 labeled EdU and Alexa647 labeled AHA can subtract the cellular background contribution calibrated from 2940 cm.sup.1 channel and can be expressed in the following the exemplary matrix:
[0353] Therefore, concentration of each labeled molecules can be solved by:
[0354] Each fluorophore cross section number can be measured using about a 500 M solution in each channel by SRS under the same power and acquisition time as in final the cellular imaging condition. Therefore, the solved molecule concentrations can be in the unit(s) of M.
[0355]
Example 4: Super-Vibrational Multiplex Imaging
Exemplary Stimulated Raman Scattering (SRS) Microscopy.
[0356] An integrated laser (e.g., picoEMERALD with custom modification, Applied Physics & Electronics, Inc.) was used as light source for both pump and Stokes beams. Briefly, picoEMERALD provided an output pulse train at 1064 nm with 6-s pulse width and 80 MHz repetition rate, which served as the Stokes beam. The frequency-doubled beam at 532 nm was used to synchronously seed a picosecond optical parametric oscillator (OPO) to produce a mode-locked pulse train (e.g., the idler beam of the OPO was blocked with an interferometric filter) with 56 ps pulse width. The wavelength of the OPO was tunable from 720 to 990 nm, which served as the pump beam. The intensity of the 1064 nm Stokes beam was modulated sinusoidally by a built-in electro-optic modulator (EOM) at 8 MHz with a modulation depth of more than 95%. The pump beam was spatially overlapped with the Stokes beam with a dichroic mirror inside picoEMERALD. The temporal overlap between pump and Stokes pulse trains was ensured with a built-in delay stage and optimized by the SRS signal of deuterium oxide (e.g., 99.9 atom % D, 151882 ALDRICH).
[0357] Pump and Stokes beams were coupled into an inverted laser-scanning microscope (e.g., FV1200MPE, Olympus) optimized for near IR throughput. A 25 water objective (e.g., XLPlan N, 1.05 N.A., MP, Olympus) with both high near IR transmission and large field of view was used for measurements of all solutions, cells and tissues unless specified. A 60 water objective (e.g., UPlanAPO/IR, 1.2
[0358] N.A., Olympus) with high near IR transmission was used for X-gal assay and live-cell 8-color imaging. The pump/Stokes beam size was matched to fill the back-aperture of the corresponding objectives for imaging. The forward going pump and Stokes beams after passing through the samples were collected in transmission with a high N.A. condenser lens (e.g., oil immersion, 1.4 N.A., Olympus), which was aligned following Kohler illumination. A telescope was then used to image the scanning mirrors onto a large area (e.g., 10 mm by 10 mm) Si photodiode (e.g., FDS1010, Thorlabs) to descan beam motion during laser scanning. The photodiode was reverse-biased by 64 V from a DC power supply to increase both the saturation threshold and response bandwidth. A high O.D. bandpass filter (e.g., 890/220 CARS, Chroma Technology) was used to block the Stokes beam completely and transmit the pump beam only. The output current of the photodiode was electronically pre-filtered by an 8 MHz band-pass filter (e.g., KR 2724, KR electronics) to suppress both the 80 MHz laser pulsing and the low-frequency contribution due to laser scanning across the scattering sample. It was then fed into a radio frequency lock-in amplifier (e.g., SR844, Stanford Research Systems or HF2LI, Zurich instrument) terminated with 50 to demodulate the stimulated Raman loss signal experienced by the pump beam. The in-phase X-output of the lock-in amplifier was fed back into the analog interface box (e.g., FV10-ANALOG) of the microscope. All laser powers were measured after objective lens. For spectroscopy measurement in
Exemplary Stimulated Raman Scattering (SRS) Spectra Acquisition
[0359] Stimulated Raman scattering spectra for all dyes were acquired by fixing the Stokes beam at 1064 nm, and scanning the pump beam through the designated wavelength range point by point.
Exemplary Linear Combination Procedure
[0360] Since epr-SRS signals are linearly dependent on analyte concentrations, quantitatively distinguishing different dyes with overlapped Raman bands could be performed through a simple and robust linear combination procedure. The measured N-channel epr-SRS signals (S) for N dyes could be expressed as the products of a NN dye Raman cross-section matrix (M) and dye concentrations (C), with addition of the cellular amide backgrounds in each channels (B):
S=M.Math.C+B
[0361] Dye concentrations were thus solved by, for example:
For
C=M.sup.1.Math.S
[0362] The procedure was implemented by a Matlab program.
[0363] Protein Labeling with Dye NHS Esters.
[0364] 1) Conjugation to secondary antibodies: Dye NHS esters were dissolved in DMSO to a concentration of 2 mg/mL. Secondary antibodies were dissolved/diluted to 2 mg/mL in PBS buffer of a pH of 8.3, adjusted with sodium bicarbonate buffer. For antibodies purchased with concentrations lower than 2 mg/mL, proteins were first concentrated with Amicon Ultra Centrifugal Filters (e.g., UFC501096, EMD, Millipore). A 50 L dye-NHS solution was slowly added to a 0.5 mL protein solution. Reaction was incubated at RT for 60 min under constant but slow stirring. The labeled proteins could be separated from unreacted dye NHS esters by gel permeation chromatography with Sephadex G-25 (e.g., G25150 SIGMA) with a column of diameter around 1 cm and length longer than 12 cm. Sephadex G-25 was first swelled in PBS buffer at 90 C. water bath for 1 h. After gel settling down in room temperature, buffer was exchange to fresh PBS buffer and gels were stored at 4 C. For gel chromatography, column was packed with swelled gels, and then equilibriumed with PBS. The labeled protein solution was then loaded and eluted with PBS buffer. First band with light color for dye conjugated proteins was collected. This solution was then centrifuged and supernatant was collected and concentrated with Amicon Ultra Centrifugal Filters (e.g., UFC501096, EMD, Millipore) into a final concentration of 1-2 mg/mL in PBS with 30% glycerol and 5 mM sodium azide and stored at 20 C.
[0365] 2) Conjugation to Wheat Germ Agglutinin (e.g., WGA, L0636 SIGMA): All procedures were the same as described above except the dye-protein ratio: a 17.5 L 2 mg/ml dye-NHS solution was slowly added to a 0.5 mL 2 mg/ml WGA solution.
[0366] Sample information (e.g., cell, tissues, antibodies and chemical reagents).
[0367] All samples were made into imaging chambers using an imaging spacer (e.g., GBL654008 SIGMA) between a coverslip and a microscope slide. The chamber was filled with PBS for imaging. All imaging results were experimentally replicated for more than 5 times.
[0368] Cell lines: Cell lines were purchased from ATCC: HeLa (e.g., ATCC CCL-2); MCF7 (e.g., ATCC HTB-22); HEK 293T/17 (e.g., ATCC CRL-11268). These cell lines were authenticated and mycoplasma negative. Cell medium: DMEM medium was made of 90% DMEM (e.g., 11965, Invitrogen), 10% FBS (e.g., 10082, Invitrogen) and 1 penicillin/streptomycin (15140, Invitrogen). Methionine-deficient DMEM medium was made by supplying 4 mM L-glutamine, 0.2 mM L-cysteine, 10% FBS and 1% penicillin/streptomycin to DMEM without L-methionine, L-cysteine and L-glutamine (e.g., D0422 SIGMA).
[0369] Mice and tissues: The animal experimental protocol (e.g., AC-AAAQ2457) was approved by the Institutional Animal Care and Use Committee at Columbia University. 400 m thick cerebellar brain slices from P11 wild-type (e.g., C57BL/6) mice of either sex were cultured with Methionine-deficient brain slice culture medium containing 1 mM AHA and 100 M EdU for 17 h. Organotypic slices were then fixed with 4% PFA for 30 min, followed with 0.5% Triton permeabilization for overnight at 4 C. No statistical method was used to predetermine sample size. All experimental procedures were performed in a non-blinded manner and no randomization was applied.
[0370] Antibodies: Primary antibodies for single-color labeling: Anti-Fibrillarin antibodyNucleolar Marker in rabbit (e.g., ab5821,Abcam); Anti-200 kD Neurofilament Heavy antibody in rabbit (e.g., ab8135, Abcam); Anti-a-Tubulin antibody in rabbit (e.g., ab18251, Abcam); Anti-Tom20 Antibody in rabbit (e.g., sc-11415, Santa Cruz Biotechnology); Anti-Giantin antibody in rabbit (e.g., ab24586, Abcam); Anti-Cytokeratin 18 antibody in mouse (e.g., ab7797, Abcam); Anti-CD44 antibody in mouse (e.g., ab6124, Abcam); Anti-EpCAM antibody in rabbit (e.g., ab71916, Abcam); Anti-IGF1 Receptor beta subunit antibody in mouse (e.g., ab80547, Abcam). For multicolor labeling: Anti-Fibrillarin antibodyNucleolar Marker in mouse (e.g., ab4566, Abcam); Anti-a-Tubulin antibody in chicken (e.g., ab89984, Abcam); Anti-Giantin antibody in rabbit (e.g., ab24586, Abcam); Anti-III-tubulin in chicken (e.g., ab107216, Abcam); Anti-Myelin Basic protein in mouse (e.g., ab62631, Abcam); Anti-GFAP in goat (e.g., ab53554, Abcam); Anti-Nestin in rat (e.g., ab81462, Abcam); Anti-NeuN in rabbit (e.g., ab177487, Abcam). Secondary antibodies: Goat-anti-rabbit ATTO740 antibody (e.g., 49559, Sigma); Goat-anti-mouse ATTO740 antibody (e.g., 2111, Hypermol); Goat-anti-rabbit ATTO700 antibody (e.g., 2310, Hypermol); Goat anti-chicken CF640R antibody (e.g., 20084, Biotium); Donkey-anti-rabbit Alexa568 (e.g., ab175692, Abcam); Donkey-anti-rat Alexa488 (e.g., abl50153, Abcam). Donkey-anti-mouse antibody (e.g., Sigma, SAB3701101), Donkey-anti-chicken (e.g., Invitrogen, SA172002) and Donkey-anti-goat antibody (e.g., Sigma, G6638) were conjugated with MARS dyes.
Fluorophores: ATTO740 NHS Ester (e.g., 59808 SIGMA), IR895 (e.g., 392375 SIGMA).
[0371] Experimental Procedures for Epr-SRS Imaging
[0372] Imaging newly synthesized DNA in HeLa cells by metabolic incorporation of 5-Ethynyl-2-deoxyuridine (e.g., EdU, T511285, Aldrich) and detection with ATTO740-azide (e.g.,
[0373] HeLa cells were seeded on a coverslip in a petri-dish with DMEM for 20 h, and then replaced with DMEM medium without FBS for another 20 h for synchronization. 10 M EdU in fresh DMEM medium were then added to cells for 15 h. Cells were fixed with 4% PFA for 20 min, permeabilized with 0.5% Triton permeabilization for 10 min. 1 M ATTO740-azide (e.g., AD 740-101, ATTO-TEC) in Click-iT Cell Reaction Buffer (e.g., C10269, Invitrogen) was then added to cells to react with EdU for 20 min. Cells were washed twice with PBS before imaging.
[0374] Immuno-Staining for Single-Color Epr-SRS Imaging of Fixed HeLa or MCF7 Cells (e.g.,
[0375] HeLa/MCF7 cells were seeded on a coverslip in a petri-dish with 2 mL of DMEM for 20 h, and then fixed with 4% PFA for 20 min or methanol for 25 min. After fixation, cells were washed with 10% goat serum/1% BSA/0.3 M glycine solution twice before permeabilization in 0.1% Tween PBS for 40 min. Primary antibody was subsequently added by 1:200 dilution in 3% BSA at 4 C. overnight. After blocking with 10% goat serum for 30 min, secondary antibody conjugated with fluorophores was added by 1:100 dilution in 10% goat serum at 4 C. overnight. The samples were blocked with 10% goat serum for 30 min before imaging.
[0376] Epr-SRS Imaging of SiR-SNAP-Tagged H2B Proteins (e.g.,
[0377] HEK293T cells were seeded on a coverslip in a petri-dish with DMEM for 20 h before transfected with 250 ng SNAP-H2B plasmid (e.g., New England BioLabs) for 48 h. 10 M SNAP-SiR (e.g., S9102S, New England BioLabs) were then added to medium for 45 min at 37 C. Cells were washed 3 times with PBS before imaging.
[0378] Epr-SRS Imaging of Mitotracker Deep Red (e.g.,
[0379] 500 nM MitoTracker deep red (e.g., M22426, Invitrogen) in HBSS was added to cells for 20 min at 37 C. Cells were washed twice with PBS before imaging.
[0380] Epr-SRS Imaging of Methylene Blue (e.g.,
[0381] 10 M methylene blue (e.g., M9140 SIGMA-ALDRICH) in PBS was added to cells for 20 min at 37 C. Cells were washed twice with PBS before imaging.
[0382] Epr-SRS imaging of the indigo product from X-gal gene expression assay (e.g.,
[0383] 8-Color Epr-SRS and Fluorescence Imaging of Fixed HeLa Cells (e.g.,
[0384] HeLa cells were seeded on a coverslip in a petri-dish with DMEM for 20 h, and then replaced with methionine-deficient DMEM medium for 30 min. 1 mM L-Azidohomoalanine (e.g., AHA, C10102, Invitrogen) and 100 M EdU were then added into medium for 18 h. 400 nM MitoTracker Orange CMTMRos (e.g., M-7510, Invitrogen) was added into medium for 30 min and 2 M Alexa 488-WGA (e.g., W11261, Invitrogen) was added together for the last 15 min before fixation of the cells with 4% PFA for 8 min followed with methanol for 20 min. The following immuno-staining procedures were same as described above. After secondary-antibody incubation, samples were blocked with 10% goat serum for 30 min. Then 5 M Cy5.5-azide (e.g., 178, AAT-Bioquest) with Click-iT Cell Reaction Buffer was added to cells to react with EdU for 20 min. After washing with PBS, 2.5 M Alexa 647-alkyne (e.g., A10278, Invitrogen) with Click-iT Cell Reaction Buffer was added to cells to react with AHA for 20 min. Lastly, NucBlue Fixed Cell ReadyProbes Reagent (e.g., R37606, Invitrogen) was added to cells for 10 min. Cells were washed with PBS before imaging.
[0385] 8-Color Epr-SRS and Fluorescence Imaging of Live HeLa Cells (e.g.,
[0386] HeLa cells were first seeded on coverslips in petri dishes with DMEM culture medium at 37 C. for 24 h. ER-GFP (e.g., C10590, Invitrogen) and Actin-RFP (e.g., C10583, Invitrogen) plasmids were transfected into cells for 48 h following the protocol from Invitrogen. 500 M oleic acid (e.g., 01383 SIGMA) coupled with BSA in DMEM culture medium was then added to cells for 7 h to induce the formation of lipid droplets. Before imaging, cells were first incubated with 6 M SYTO60 (e.g., S11342, Invitrogen), 120 nM LysoTracker Deep Red (e.g., L12492, Invitrogen) and 400 nM Rhodamine 800 (e.g., 83701 SIGMA) in HBSS simultaneously for 30 min at 37 C., followed by staining with NucBlue Live ReadyProbes Reagent (e.g., R37605, Invitrogen) in HBSS for 20 min at 37 C. Then cells were incubated with ATTO 740-conjugated WGA in HBSS for 30 min at 37 C., followed by staining with LipidTOX Deep Red (e.g., H34477, Invitrogen) in HBSS with a dilution of 1:20 for 30 min at room temperature before imaging.
[0387] 16-Color Epr-SRS and Fluorescence Imaging of Live HeLa Cells (e.g.,
[0388] HeLa cells were first seeded in 24-well dish for 20 h. Each well of cells were labeled with a single color of epr-SRS or fluorescent dyes for 30 min in PBS: MARS2237 (e.g., 1 M), MARS2228 (e.g., 4 M), MARS2209 (e.g., 1 M), MARS2200 (e.g., 4 M), MARS2183 (e.g., 1 M), MARS2176 (e.g., 4 M), MARS2154 (e.g., 1 M), MARS2147 (e.g., 4 M), ATTO OXA12 (e.g., 10 M), Cy5.5 (e.g., 2 M), MitoTracker deep red (e.g., 2.5 M), SYTO60 (e.g., 10 M). FM 4-64 (e.g., T13320, Invitrogen, 20 g/ml), MitoTracker orange (e.g., M7510, Invitrogen, 400 nM), Alexa488-WGA (e.g., W11261, Invitrogen, 2 g/ml), Nucblue (e.g., R37605, Invitrogen). Cells were then washed with PBS and detached from each well by trypsin treatment for 2 min; then mixed together in fresh DMEM medium before gently centrifuge (e.g., 1000 rpm, 1.5 min) to pellet. PBS was added to the pellet and after gentle mix; cells were sandwiched in imaging chamber. After settling down for 15-20 min on imaging stage to reduce cell movement, images were acquired. Single dye staining and 2-color mix were first examined and no cross staining between cells was found during the imaging period (e.g., i.e. each cell was maintained with a single pre-stained color). Obvious stage drift was not observed during 16-color image acquisitions.
[0389] 8-Color Epr-SRS and Fluorescence Imaging of Hippocampal Neuronal Cultures and Cerebellar Brain Slices (e.g.,
[0390] Regular hippocampal neuron medium was made of Neurobasal A Medium (e.g., 10888, Invitrogen), 1B27 serum free supplement (e.g., 17504, Invitrogen) and 0.5 mM glutamine (e.g., 25030, Invitrogen). Methionine-deficient neuron medium was custom made from regular recipe of Neurobasal A medium (e.g., 10888, Invitrogen) without methionine, and supplied with 1B27 serum free supplement and 0.5 mM glutamine. Methionine-deficient medium for organotypic cerebellar brain slices was made by supplying methionine-deficient neuron medium with 1B27 serum free supplement, 2 mM glutamine, 0.5% glucose and 1% penicillin/streptomycin. Regular medium in D9 hippocampal neuronal cultures was first replaced by methionine-deficient medium containing 1 mM AHA and 100 M EdU for 17 h. Cells were then fixed with 4% PFA for 20 min, followed with 0.5% Triton permeabilization for 15 min. Primary antibodies were then simultaneously added with 1:120 dilution in 3% BSA for overnight at 4 C. After blocking with 10% donkey serum for 30 min, secondary antibodies conjugated with fluorophores were added with 1:80 dilution in 10% donkey serum for overnight at 4 C. Samples were blocked with 10% donkey serum for 30 min with NucBlue Fixed Cell ReadyProbes Reagent added for the last 10 min. Then 1 M MARS2228-azide with Click-iT Cell Reaction Buffer was added to cells/slices to react with EdU for 20 min. After washing with PBS, 12 M Alexa 647-alkyne with Click-iT Cell Reaction Buffer was added to react with AHA for 20 min. Cells were washed with PBS before imaging. 8-color epr-SRS and fluorescence imaging in neuronal cultures (e.g.,
[0391] Regular Medium of D12 hippocampal neuronal cultures was replaced by methionine-deficient medium containing 1 mM L-Homopropargylglycine (e.g., HPG, C10186, Invitrogen) for 12 h. The medium was then exchanged to fresh methionine-deficient medium containing 1 mM AHA with or without 10 M MG132 (e.g., M7449 SIGMA) for another 10 h. Cells were fixed with 4% PFA for 20 min, permeabilized with 0.5% Triton for 15 min. The immuno-staining procedures were the same as described above. Then 1.25 M MARS2228-azide with Click-iT Cell Reaction Buffer was added to cells/slices to react with HPG for 20 min. After washing with PBS, 4 M Alexa 647-alkyne with Click-iT Cell Reaction Buffer was added to react with AHA for 20 min. Cells were washed with PBS before imaging.
[0392] Image Statistics for
[0393] 6 technical replicates of 8-colour images were acquired from 3 independent neuronal co-cultures (e.g., the same condition as described above for
[0394] Live/dead cell viability assay: It can be performed using the LIVE/DEAD viability/cytotoxicity kit for mammalian cells (e.g., Molecular Probes L-3224). HeLa cell standards and HeLa cells with dye staining or SRS pre-exposure were incubated with 2 M calcein AM and 4 M EthD-1 working solution for 20 minutes at 37 C. before imaging.
[0395] Data and code availability All data supporting this study are available from the corresponding author on request.
[0396] As shown in
[0397] Further, the exemplary processing arrangement 4905 can be provided with or include an input/output arrangement 4935, which can include, for example a wired network, a wireless network, the internet, an intranet, a data collection probe, a sensor, etc. As shown in
[0398] The foregoing merely illustrates the principles of the disclosure. Various modifications and alterations to the described exemplary embodiments will be apparent to those skilled in the art in view of the teachings herein. It will thus be appreciated that those skilled in the art will be able to devise numerous systems, arrangements, and procedures which, although not explicitly shown or described herein, embody the principles of the disclosure and can be thus within the spirit and scope of the disclosure. Various different exemplary embodiments can be used together with one another, as well as interchangeably therewith, as should be understood by those having ordinary skill in the art. In addition, certain terms used in the present disclosure, including the specification, drawings and claims thereof, can be used synonymously in certain instances, including, but not limited to, e.g., data and information. It should be understood that, while these words, and/or other words that can be synonymous to one another, can be used synonymously herein, that there can be instances when such words can be intended to not be used synonymously. Further, to the extent that the prior art knowledge has not been explicitly incorporated by reference herein above, it is explicitly incorporated herein in its entirety. All publications referenced are incorporated herein by reference in their entireties.
EXEMPLARY REFERENCES
[0399] The following references are hereby incorporated by reference in their entireties: [0400] 1. Chalfie M, Tu Y, Euskirchen G, Ward W W P D (1994) Green fluorescent protein as a marker gene expression. Science 263:802-804. [0401] 2. Tsien R Y (1998) The Green Fluorescent. Annu. Rev. Biochemistry 67:509-544. [0402] 3. Resch-Genger U, Grabolle M, Cavaliere-Jaricot S, Nitschke R N T (2008) Quantum dots versus organic dyes as fluorescent labels. Nature methods 5:763-775. [0403] 4. Miyawaki A, Sawano A, Kogure T (2003) Lighting up cells: labelling proteins with fluorophores. Nature cell biology. [0404] 5. Knoll B, Keilmann F (1999) Near-field probing of vibrational absorption for chemical microscopy. Nature 399:7-10. [0405] 6. Turrell G, Corset J (1996) raman microscopy developments and application [0406] 7. Evans C L, Xie X S (2008) Coherent anti-stokes Raman scattering microscopy: chemical imaging for biology and medicine. Annual review of analytical chemistry (Palo Alto, Calif.) 1:883-909. [0407] 8. Freudiger C, Min W, Saar B, Lu S, Holtom G (2008) Label-free biomedical imaging with high sensitivity by stimulated Raman scattering microscopy. Science 322:1857-1861. [0408] 9. Min W, Freudiger C W, Lu S, Xie X S (2011) Coherent nonlinear optical imaging: beyond fluorescence microscopy. Annual review of physical chemistry 62:507-30. [0409] 10. Prescher J a, Bertozzi C R (2005) Chemistry in living systems. Nature chemical biology 1:13-21. [0410] 11. Sletten E M, Bertozzi C R (2009) Bioorthogonal chemistry: fishing for selectivity in a sea of functionality. Angewandte Chemie (International ed. in English) 48:6974-98. [0411] 12. Lim R K V, Lin Q (2010) Bioorthogonal chemistry: recent progress and future directions. Chemical communications (Cambridge, England) 46:1589-600. [0412] 13. Yamakoshi H et al. (2011) Imaging of EdU, an alkyne-tagged cell proliferation probe, by Raman microscopy. Journal of the American Chemical Society 133:6102-5. [0413] 14. Yamakoshi H et al. (2012) Alkyne-tag Raman imaging for visualization of mobile small molecules in live cells. Journal of the American Chemical Society 134:20681-9. [0414] 15. Bloembergen N (1967) The Stimulated Raman Effect. American Journal of Physics 35:989-1023. [0415] 16. Masters B R, So P T C, Mantulin W W (2008) Handbook of biomedical nonlinear optical microscopy. eds Masters B R, So P T C (Oxford University Press) [0416] 17. Saar B G et al. (2010) Video-rate molecular imaging in vivo with stimulated Raman scattering. Science (New York, N.Y.) 330:1368-70. [0417] 18. Salic A, Mitchison T J (2008) A chemical method for fast and sensitive detection of DNA synthesis in vivo. Proceedings of the National Academy of Sciences of the United States of America 105:2415-20. [0418] 19. Neef A B, Luedtke N W (2011) Dynamic metabolic labeling of DNA in vivo with arabinosyl nucleosides. Proceedings of the National Academy of Sciences of the United States of America 108:20404-9. [0419] 20. Jao C Y, Salic A (2008) Exploring RNA transcription and turnover in vivo by using click chemistry. Proceedings of the National Academy of Sciences of the United States of America 105:15779-84. [0420] 21. Beatty K E et al. (2006) Fluorescence visualization of newly synthesized proteins in mammalian cells. Angewandte Chemie (International ed. in English) 45:7364-7. [0421] 22. Liu J, Xu Y, Stoleru D, Salic A (2012) Imaging protein synthesis in cells and tissues with an alkyne analog of puromycin. Proceedings of the National Academy of Sciences of the United States of America 109:413-8. [0422] 23. Jao C Y, Roth M, Welti R, Salic A (2009) Metabolic labeling and direct imaging of choline phospholipids in vivo. Proceedings of the National Academy of Sciences of the United States of America 106:15332-7. [0423] 24. Hershey J W B, Sonenberg N, Mathews M B Eds. (2012) Protein synthesis and translational control. Cold Spring Harbor Laboratory Press. [0424] 25. Martin K C, Barad M, Kandel E R (2000) Local protein synthesis and its role in synapse-specific plasticity. Curr. Opin. Neurobiol. 10:587-592. [0425] 26. Kandel E R (2001) The molecular biology of memory storage: a dialogue between genes and synapses. Science 294:1030-1038. [0426] 27. Ho V M, Lee J A, Martin K C (2011) The cell biology of synaptic plasticity. Science 334:623-628. [0427] 28. Chalfie M, Tu Y, Euskirchen G, Ward W W, Prasher D C (1994) Green fluorescent protein as a marker for gene expression. Science 263:802-805. [0428] 29. Tsien R Y (1998) The green fluorescent protein. Annu. Rev. Biochem. 67:509-544. [0429] 30. Dieterich D C, Link A J, Graumann J, Tirrell D A, Schuman E M (2006) Selective identification of newly synthesized proteins in mammalian cells using bioorthogonal noncanonical amino acid tagging (BONCAT). Proc. Natl. Acad. Sci. USA 103:9482-9487. [0430] 31. Beatty K E et al. (2006) Fluorescence visualization of newly synthesized proteins in mammalian cells. Angew. Chem. 45:7364-7367. [0431] 32. Beatty K E, Tirrell D A (2008) Two-color labeling of temporally defined protein populations in mammalian cells. Bioorg. Med. Chem. Lett. 18:5995-5999. [0432] 33. Roche F K, Marsick B M, Letourneau P C (2009) Protein synthesis in distal axons is not required for growth cone responses to guidance cues. J Neurosci. 29:638-652. [0433] 34. Dieterich D C et al. (2010) In situ visualization and dynamics of newly synthesized proteins in rat hippocampal neurons. Nat. Neurosci. 13:897-905. [0434] 35. Tcherkezian J, Brittis P A, Thomas F, Roux P P, Flanagan J G (2010) Transmembrane receptor DCC associates with protein synthesis machinery and regulates translation. Cell 141:632-644. [0435] 36. Hinz F I, Dieterich D C, Tirrell D A, Schuman E M (2012) Non-canonical amino acid labeling in vivo to visualize and affinity purify newly synthesized proteins in larval zebrafish. ACS Chem. Neurosci. 3:40-49. [0436] 37. Liu J, Xu Y, Stoleru D, Salic A (2012) Imaging protein synthesis in cells and tissues with an alkyne analog of puromycin. Proc. Natl. Acad. Sci. USA 109:413-418. [0437] 38. Boyce M, Bertozzi C R (2011) Bringing chemistry to life. Nat. Methods 8:638-642. [0438] 39. Schoenheimer R, Rittenberg D (1936) Deuterium as an indicator in the study of intermediary metabolism. J. Biol. Chem. 111:163-168. [0439] 40. Schoenheimer R, Rittenberg D (1938) Application of isotopes to the study of intermediary metabolism. Science 87:221-226. [0440] 41. Ong S E et al. (2002) Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell. Proteomics 1:376-386. [0441] 42. Mann M (2006) Functional and quantitative proteomics using SILAC. Nat. Rev. Mol. Cell. Biol. 7:952-958. [0442] 43. Harsha H C, Molina H, Pandey A (2008) Quantitative proteomics using stable isotope labeling with amino acids in cell culture. Nat. Protoc. 3:505-516. [0443] 44. Geiger T et al. (2011) Use of stable isotope labeling by amino acids in cell culture as a spike-in standard in quantitative proteomics. Nat. Protoc. 6:147-157. [0444] 45. Ingolia N T, Lareau L F, Weissman J S (2011) Ribosome profiling of mouse embryonic stem cells reveals the complexity and dynamics of mammalian proteomes. Cell. 147:789-802. [0445] 46. Potma E O, Xie X S (2008) Theory of spontaneous and coherent Raman scattering in Handbook of Biomedical Nonlinear Optical Microscopy; Masters B R, So P T C Eds. [0446] Oxford University Press: New York, N.Y., USA. [0447] 47. Zumbusch A, Holtom G R, Xie X S (1999) Three-dimensional vibrational imaging by coherent anti-Stokes Raman scattering. Phys. Rev. Lett. 82:4142-4145. [0448] 48. Evans C L, Xie X S (2008) Coherent anti-Stokes Raman scattering microscopy: chemical imaging for biology and medicine. Annu. Rev. Anal. Chem. 1:883-909. [0449] 49. Cheng J X, Xie X S (2004) Coherent anti-Stokes Raman scattering microscopy: instrumentation, theory, and applications. J. Phys. Chem. B 108:827-840. [0450] 50. Pezacki J P et al. (2011) Chemical contrast for imaging living systems: molecular vibrations drive CARS microscopy. Nat. Chem. Biol. 7:137-145. [0451] 51. Suhalim J L, Boik J C, Tromberg B J, Potma E O (2012) The need for speed. J. Biophotonics 5:387-95. [0452] 52. Ploetz E, Laimgruber S, Berner S, Zinth W, Gilch P (2007) Femtosecond stimulated Raman microscopy. Appl. Phys. B 87:389-393. [0453] 53. Freudiger C W et al. (2008) Label-free biomedical imaging with high sensitivity by stimulated Raman scattering microscopy. Science 322:1857-1861. [0454] 54. Ozeki Y, Dake F, Kajiyama S, Fukui K, Itoh K (2009) Analysis and experimental assessment of the sensitivity of stimulated Raman scattering microscopy. Opt. express. 17:3651-3658. [0455] 55. Nandakumar P, Kovalev A, Volkmer A (2009) Vibrational imaging based on stimulated Raman scattering microscopy. New J. Phys. 11:033026. [0456] 56. Saar B G et al. (2010) Video-rate molecular imaging in vivo with stimulated Raman scattering. Science 330:1368-1370. [0457] 57. Zhang D, Slipchenko M N, Cheng J X (2011) Highly sensitive vibrational imaging by femtosecond pulse Stimulated raman Loss. J. Phys. Chem. Lett. 2:1248-1253. [0458] 58. Wang M C, Min W, Freudiger C W, Ruvkun G, Xie X S (2011) RNAi screening for fat regulatory genes with SRS microscopy. Nat. methods 8:135-138. [0459] 59. Zhang X et al. (2012) Label-free live-cell imaging of nucleic acids using stimulated Raman scattering microscopy. Chemphyschem. 13:1054-1059. [0460] 60. Fu D et al. (2012) Quantitative chemical imaging with multiplex stimulated Raman scattering microscopy. J. Am. Chem. Soc. 134: 3623-3626. [0461] 61. Ozeki Y et al. (2012) High-speed molecular spectral imaging of tissue with stimulated Raman scattering. Nature Photon. 6:845-851. [0462] 62. Einstein A (1917) On the quantum theory of radiation. Phys. Z. 18:121-128. [0463] 63. Bloembergen N (1967) The Stimulated Raman Effect. Am. J. Phys. 35:989-1023. [0464] 64. Min W, Freudiger C W, Lu S, Xie X S (2011) Coherent nonlinear optical imaging: beyond fluorescence microscopy. Annu Rev Phys Chem. 62:507-530. [0465] 65. Min W (2011) Label-free optical imaging of nonfluorescent molecules by stimulated radiation. Curr. Opin. Chem. Biol. 15:831-837. [0466] 66. Okayasu T, Ikeda M, Akimoto K, Sorimachi K (1997) The amino acid composition of mammalian and bacterial cells. Amino Acids 13:379-391. [0467] 67. Phair R D and Misteli T (2000) High mobility of proteins in the mammalian cell nucleus. Nature 404: 604-609. [0468] 68. Andersen J S et al. (2005) Nucleolar proteome dynamics. Nature 433:77-83. [0469] 69. Boisvert F M et al. (2012) A quantitative spatial proteomics analysis of proteome turnover inhuman cells. Mol. Cell. Proteomics. 11(3): M111.011429. [0470] 70. Piez K A and Eagle H (1958) The free amino acid pool of cultured human cells. J. Biol. Chem. 231: 533-545 [0471] 71. Lechene C P, Luyten Y, McMahon G, Distel D L (2007) Quantitative imaging of nitrogen fixation by individual bacteria within animal cells. Science 317:1563-1566. [0472] 72. Zhang D S et al. (2012) Multi-isotope imaging mass spectrometry reveals slow protein turnover in hair-cell stereocilia. Nature 481:520-524. [0473] 73. van Manen H J, Lenferink A, Otto C (2008) Noninvasive imaging of protein metabolic labeling in single human cells using stable isotopes and Raman microscopy. Anal. chem. 80:9576-9582. [0474] 74. Ji Minbiao et al. (2013) Rapid, label-free detection of brain tumors with stimulated Raman scattering miscroscopy. Sci. Transl. Med. 5(201): 201ra119. [0475] 76. Saar et al. (2011) Imaging drug delivery to skin with stimulated Raman scattering microscopy. Mol. Pharm. 8(3): 969-75. [0476] 77. Cui et al. (2009) Comparing coherent and spontaneous Raman scattering under biological imaging conditions. Opt. Lett. 34(16): 773-775. [0477] 78. Petrov et al. (2007) Comparison of coherent and spontaneous Raman microspectroscopies for noninvasive detection of single bacterial endospores. Proc. Natl. Acad. Sci. USA. 104(19): 7776-9. [0478] 79. Nie, S., Chiu, D. T. & Zare, R. N. Probing individual molecules with confocal fluorescence microscopy. Science 266, 1018-1021 (1994). [0479] 80. Moerner, W. E. & Orrit, M. Illuminating single molecules in condensed matter. Science 283, 1670-1676 (1999). [0480] 81. Yuste, R. Fluorescence microscopy today. Nat. Methods 2, 902-904 (2005). [0481] 82. Denk, W., Strickler, J. H. & Webb, W. W. Two-photon laser scanning fluorescence microscopy. Science 248, 73-76 (1990). [0482] 83. Hell, S. W. & Wichmann, J. Breaking the diffraction resolution limit by stimulated emission: stimulated-emission-depletion fluorescence microscopy. Opt. Lett. 19, 780-2 (1994). [0483] 84. Betzig, E. et al. Imaging intracellular fluorescent proteins at nanometer resolution. Science 313, 1642-1645 (2006). [0484] 85. Rust, M. J., Bates, M. & Zhuang, X. Sub-diffraction-limit imaging by stochastic optical reconstruction microscopy (STORM). Nat. Methods 3, 793-795 (2006). [0485] 86. Ha, T. et al. Probing the interaction between two single molecules: fluorescence resonance energy transfer between a single donor and a single acceptor. Proc. Natl. Acad. Sci. U.S.A 93, 6264-6268 (1996). [0486] 87. Myers, A B. Molecular electronic spectral broadening in liquids and glasses. Annu. Rev. Phys. Chem. 49, 267-295 (1998). [0487] 88. Nemkovich, N., Rubinov, A. & Tomin, V. Inhomogeneous Broadening of Electronic Spectra of Dye Molecules in Solutions. Top. Fluoresc. Spectrosc. SE-8 2, 367-428 (2002). [0488] 89. Gaiduk, A., Yorulmaz, M., Ruijgrok, P. V & Orrit, M. Room-temperature detection of a single molecule's absorption by photothermal contrast. Science 330, 353-356 (2010). [0489] 90. Chong, S., Min, W. & Xie, X. S. Ground-state depletion microscopy: Detection sensitivity of single-molecule optical absorption at room temperature. J. Phys. Chem. Lett. 1, 3316-3322 (2010). [0490] 91. Kukura, P., Celebrano, M., Renn, A. & Sandoghdar, V. Single-molecule sensitivity in optical absorption at room temperature. J. Phys. Chem. Lett. 1, 3323-3327 (2010). [0491] 92. Giesen, C. et al. Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry. Nat. Methods 11, 417-22 (2014). [0492] 93. Angelo, M. et al. Multiplexed ion beam imaging of human breast tumors. Nat. Med. 20, 436-42 (2014). [0493] 94. Barlogie, B. et al. Flow Cytometry in Clinical Cancer Research Flow Cytometry in Clinical Cancer Researchl. 43, 3982-3997 (1983). [0494] 95. Geiger, B., Spatz, J. P. & Bershadsky, A. D. Environmental sensing through focal adhesions. Nat. Rev. Mol. Cell Biol. 10, 21-33 (2009). [0495] 96. Cheng, J.-X. & Xie, X. S. Coherent Raman Scattering Microscopy. CRC press (2012). [0496] 97. Nie, S. Probing Single Molecules and Single Nanoparticles by Surface-Enhanced Raman Scattering. Science. 275, 1102-1106 (1997). [0497] 98. Kneipp, K. et al. Single molecule detection using surface-enhanced Raman scattering (SERS). Phys. Rev. Lett. 78, 1667-1670 (1997). [0498] 99. Freudiger, C., Min, W., Saar, B., Lu, S. & Holtom, G. Label-free biomedical imaging with high sensitivity by stimulated Raman scattering microscopy. Science (80-.). 322, 1857-1861 (2008). [0499] 100. Min, W., Freudiger, C. W., Lu, S. & Xie, X. S. Coherent nonlinear optical imaging: beyond fluorescence microscopy. Annu. Rev. Phys. Chem. 62, 507-530 (2011). [0500] 101. Saar, B. G. et al. Video-rate molecular imaging in vivo with stimulated Raman scattering. Science 330, 1368-1370 (2010). [0501] 102. Ji, M. et al. Rapid, label-free detection of brain tumors with stimulated Raman scattering microscopy. Sci. Transl. Med. 5, 201ra119 (2013). [0502] 103. Wei, L. et al. Live-cell imaging of alkyne-tagged small biomolecules by stimulated Raman scattering. Nat. Methods 11, 410-2 (2014). [0503] 104. Yamakoshi, H. et al. Alkyne-tag Raman imaging for visualization of mobile small molecules in live cells. J. Am. Chem. Soc. 134, 20681-20689 (2012). [0504] 105. Results, E. Probe-frequency dependence of the resonant Inverse Raman band shape. October 89, 3945-3950 (1988). [0505] 106. McCamant, D. W., Kukura, P. & Mathies, R. A. Femtosecond Broadband Stimulated Raman: A New Approach for High-Performance Vibrational Spectroscopy. Appl. Spectrosc. 57, 1317-1323 (2003). [0506] 107. Kim, H. M., Kim, H., Yang, I., Jin, S. M. & Suh, Y. D. Time-gated pre-resonant femtosecond stimulated Raman spectroscopy of diethylthiatricarbocyanine iodide. Phys. Chem. Chem. Phys. 16, 5312-8 (2014). [0507] 108. Asher, S. A. UV resonance Raman studies of molecular structure and dynamics: applications in physical and biophysical chemistry. Annu. Rev. Phys. Chem. 39, 537-588 (1988). [0508] 109. Lichtman, J. W. & Denk, W. The big and the small: challenges of imaging the brain's circuits, Science 334, 618-623 (2011). [0509] 110. Chen, K. H., Boettiger, A. N., Moffitt, J. R., Wang, S. & Zhuang, X. Spatially resolved, highly multiplexed RNA profiling in single cells, Science 348, 6233 (2015). [0510] 111. Giesen, C. et al. Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry, Nat. Methods 11, 417-422 (2014). [0511] 112. Shroff, H. et al. Dual-color super resolution imaging of genetically expressed probes within individual adhesion complexes, Proc. Natl. Acad. Sci. USA. 104, 20308-20313 (2007). [0512] 113. Lakowicz, J. R. Principles of Fluorescence Spectroscopy. 3rd edition (Springer, 2011). [0513] 114. Dean, K. M. & Palmer, A. E. Advances in fluorescence labeling strategies for dynamic cellular imaging, Nat. Chem. Biol. 10, 512-523 (2014). [0514] 115. Tsurui, H. et al. Seven-color fluorescence imaging of tissue samples based on fourier spectroscopy and singular value decomposition, J. Histochem. Cytochem. 48, 653-662(2000). [0515] 116. Niehorster, T. et al. Multi-target spectrally resolved fluorescence lifetime imaging microscopy. Nat. Methods 13, 257-262 (2016). [0516] 117. Lane, L. A., Qian, X. & Nie, S. SERS nanoparticles in medicine: from label-free detection to spectroscopic tagging, Chem. Rev., 115, 10489-10529 (2015). [0517] 118. Min, W., Freudiger, C. W., Lu, S. & Xie, X. S. Coherent nonlinear optical imaging: beyond fluorescence microscopy, Annu. Rev. Phys. Chem. 62, 507-530 (2011). [0518] 119. Cheng, J.-X. & Xie, X. S. Vibrational spectroscopic imaging of living systems: emerging platform for biology and medicine, Science 350, aaa8870 (2015). [0519] 120. Wei, L. et al. Live-cell imaging of alkyne-tagged small biomolecules by stimulated Raman scattering, Nat. Methods 11, 410-412 (2014). [0520] 121. Hong, S. et al. Live-cell stimulated Raman scattering imaging of alkyne-tagged biomolecules, Angew. Chem. Int. Ed. Engl. 53, 5827-5831 (2014). [0521] 122. Yamakoshi, H. et al. Imaging of EdU, an alkyne-tagged cell proliferation probe, by Raman microscopy. J. Am. Chem. Soc., 133, 6102-6105 (2011). [0522] 123. Weeks, T., Wachsmann-Hogiu, S. & Huser, T., Raman microscopy based on doubly-resonant four-wave mixing (DR-FWM), Opt. Express, 17, 17044-17051 (2009). [0523] 124. Asher, S. A. UV Resonance Raman studies of molecular structure and dynamics: applications in physical and biophysical chemistry, Annu. Rev. Phys. Chem. 39, 537-588 (1988). [0524] 125. McCamant, D. W., Kukura, P. & Mathies, P. Femtosecond broadband stimulated Raman: a new approach for high-performance vibrational spectroscopy, Appl. Spectrosc. 57, 1317-1323 (2003). [0525] 126. Le Ru, E. C. & Etchegoin, P. G. Single-molecule surface-enhanced Raman spectroscopy, Annu. Rev. Phys. Chem. 63, 65-87 (2012). [0526] 127. Albrecht, A. C. & Hutley, M. C. On the dependence of vibrational Raman intensity on the wavelength of incident light. J. Chem. Phys. 55, 4438-4443 (1971). [0527] 128. Yamakoshi, H. et al. Alkyne-tag Raman imaging for visualization of mobile small molecules in live cells, J. Am. Chem. Soc. 134, 20681-20689 (2012). [0528] 129. Shi, J., Zhang, X.-P. & Neckers, D. C. Xanthenes: Flourone Derivatives II, Tet. Lett. 34, 6013-6016 (1993). [0529] 130. Pastierik, T., ebej, P., Medalovi, J., tacko, P. & Klin, P. Near-infrared fluorescent 9-phenylethynylpyronin analogues for bioimaging, J. Org. Chem. 79, 3374-3382 (2014). [0530] 131. Koide, Y. et al. Development of NIR fluorescent dyes based on Si-Rhodamine for in vivo imaging, J Am. Chem. Soc. 134, 5029-5031 (2012). [0531] 132. Chen, Z. et al. Multicolor live-cell chemical imaging by isotopically edited alkyne vibrational palette, J Am. Chem. Soc. 136, 8027-8033 (2014). [0532] 133. Kaushik, S. & Cuervo, A. M. Proteostasis and aging, Nat. Med. 21, 1406-1415 (2015). [0533] 134. Jnen, S. B., Chaachouay, H. & Richter-Landsberg, C. Autophagy is activated by proteasomal inhibition and involved in aggresome clearance in cultured astrocytes, Glia 58, 1766-1774. (2010). [0534] 135. Goldberg, A. L. Protein degradation and protection against misfolded or damaged proteins, Nature 426, 895-899 (2003). [0535] 136. Chen, B., Retzlaff, M., Roos, T. & Frydman, J. Cellular strategies of protein quality control. Cold Spring Harb. Perspect Biol. 3, a004374 (2011). [0536] 137. Shu, X. et al. Mammalian expression of infrared fluorescent proteins engineered from a bacterial phytochrome. Science 324, 804-807 (2009). [0537] 138. Liao, C.-S. et al. Spectrometer-free vibrational imaging by retrieving stimulated Raman signal from highly scattered photons Sci. Adv. 1, e1500738 (2015). [0538] 139. Wei, L. et al. Super-multiplex vibrational imaging. Nature. 2017 Apr. 27; 544 (7651): 465-470.